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1. ABSTRACT 
 
Chemokine ligand 20 (CCL20) expressed in the epidermis is a potent impetus for the recruitment of 
subsets of DCs, B-cells and memory T-cells expressing its exclusive receptor chemokine receptor 6 (CCR6) 
into the skin. CCL20 and a corresponding CCR6-expressing immune cell infiltrate have been detected in 
chronic inflammatory skin diseases and several malignancies, including melanoma. Yet, the functional 
contribution of the CCR6/CCL20 axis for the immune control of melanoma remains controversial. The 
characterization of CCR6-guided immune cell subsets and their functional contribution for the immune 
control of melanoma comprises the main focus of this project. We evaluated the homeostatic and 
inducible secretion of CCL20 by different murine and human melanoma cell lines by ELISA. Both murine 
(B16, Ret) and human (A375, C32) melanoma cell lines are capable of up-regulating CCL20 secretion 
upon stimulation with pro-inflammatory cytokines in vitro . In order to determine the functional 
relevance of CCR6 on local tumor growth, B16/F1 melanoma cells retrovirally transduced with a vector 
that constantly overexpresses CCL20 (B16-CCL20) were injected subcutaneously in C57BL/6 wt mice and 
congenic CCR6-knockout (CCR6-/-) mice. While animals in both groups developed local tumors, we 
observed a significantly reduced tumor growth in CCR6-/- mice. By contrast, Wt and CCR6-/- control 
groups did not display differences in tumor growth rate. Our results suggest that CCL20 interactions in 
the microenvironment of cutaneous melanoma may be an essential factor for local tumor growth, 
although the precise mechanisms require further investigation. 
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1.- ZUSAMMENFASSUNG 
 
Der Chemokin ligand 20 (CCL20) wird in der Epidermis exprimiert und ist ein wichtiges Signal für die 
Rekrutierung von Chemokin Rezeptor 6 (CCR6) - exprimierenden dendritische Zellen, B-Zellen und T-
Gedächtniszellen in die Haut. CCL20 und das damit verbundene CCR6- exprimierende Immunzellinfiltrat 
konnten in chronisch entzündlichen Hauterkrankungen und verschiedenen Krebserkrankungen, wie 
Melanom, nachgewiesen werden. Die funktionelle Rolle der CCR6/CCL20 Moleküle in der Immunabwehr 
im Melanom ist noch nicht geklärt.  Die Charakterisierung der CCR6-positiven Immunzellen und deren 
funktionellen Beitrag in der Immunabwehr gegen Melanom, stellt den Hauptfokus dieser Arbeit dar. Wir 
untersuchten verschiedene murine und humane Melanom-Zelllinien auf die basale und induzierbare 
Sekretion von CCL20 mit Hilfe von ELISA. Sowohl die murinen (B16, Ret), wie auch die humanen 
(A375,C32) Melanomzelllinien sind in der Lage, CCL20 als Antwort auf pro-inflammatorisch Stimuli in 
vitro  hoch zu regulieren.  Um die funktionelle Relevanz von CCR6 auf das Tumorwachstum zu beurteilen, 
wurden CCL20 überexprimierende B16/F1 Melanomzellen (B16-CCL20)  in C57BL/6 Wildtyp (WT) Mäuse 
und C57BL/6 CCR6-Knockout Mäuse (CCR6 -/-) subkutan injiziert.  Während Tiere beider Gruppen lokale 
Tumore entwickelten, konnte ein signifikant vermindertes Tumorwachstum in CCR6 -/- Mäusen 
beobachtet werden. Im Unterschied dazu zeigen WT und CCR6 -/- Kontrollgruppen keine sichtbaren 
Unterscheidungen im Tumorwachstum. Unsere Daten deuten darauf hin, dass Interaktionen von CCL20  
im Tumormikromilieu beim kutanem Melanom möglicherweise einen essentiellen Faktor im lokalen 
Tumorwachstum besitzen, auch wenn die genauen Mechanismen dieser Interaktion noch weiter 
untersucht werden müssen.   
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2. INTRODUCTION 
2.1. Chemokines and their receptors, an historical overview 
Chemokines are small cytokines of low molecular weight (7-12 KDa) whose main function, together with 
their Chemokine receptors (CKRs), is to drive different immune cell subsets to specific anatomical 
locations. However, besides this classical function, chemokines and their receptors have emerged as 
main players in an array of biological functions in both health and disease such as infectious diseases, 
hematopoiesis, cancer metastasis angiogenesis and neural development.  
 
Although the study of chemoattractants started in late 1970s with the isolation of platelet factor 4 
(PGF4, later CXCL4), it was not till 1987 that the field of chemokine research officially started after the 
successful cloning of the CXCL8 gene and its migratory effect on neutrophils [1]. Initially CXCL8 was 
misclassified as an interleukin (IL-8) and it was not till the analysis of its 3-dimension structure that could 
be correctly classified as a bona fide chemokine. In fact, unrevealing the 3-dimension structure of 
previously described proteins contributed the identification of other chemokines, like CXCL10 [2], CCL1 
[3] and CCL3 [4]. The discovery of the first chemokines was the starting point of a race towards the 
identification of their receptors.  
In the 1990s research in the field of chemokines rapidly expanded and it soon became clear that besides 
neutrophils, chemokines could target monocytes, innate immune cells, T- and B-cells. In addition to 
chemoattraction, new roles for chemokines were described in infections and inflammatory diseases, as 
well as in homeostatic processes and embryonic development [5]. Interestingly some homeostatic 
chemokines display lethal phenotypes in gene-deficient mice, such as CXCL12 [6]. 
In the year 2000 a new official nomenclature system was adopted in order to simplify the complexity of 
the previous naming system [7]. By then, the field of chemokine research had expanded to a great array 
of research areas, including studies on malaria [8] or on the human immunodeficiency virus (HIV) [9]. 
Chemokine ligand/receptor interactions soon proved to be more complex than initially speculated: 
Chemokine receptors need to sense a chemokine gradient to be expressed [10] and during inflammation 
processes, the ligands are able to modify the inflammatory milieu through binding, uptake and 
intracellular degradation of chemokines [11].  
The fact that genes of many virus types target the chemokine system by expressing either inhibitors or 
chemokine-neutralizing proteins highlights the importance of this field of study [12].  
Introduction 
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Chemokine research is still an expanding field today. The many different and sometimes conflicting roles 
and functions of chemokine ligands/receptors make them a very attractive and interesting field of study. 
Major drug companies are investing enormous amounts of funds in chemokine research as a primary 
target in translational research. Up to date some FDA-approved compounds have emerged from these 
studies. Prominent examples are Maraviroc (Celsentri®, Pfizer), a CCR5 antagonist used as an entry 
inhibitor in the treatment of HIV-infected patients [13]; AMD3100 (Perixafor injection, Mozobil), a non-
peptide chemokine receptor inhibitor targeting CXCR4 used in hematopoietic stem cell mobilization [14]; 
and Mogamulizumab (Poteligeo®, Kowa Hakko Kirin, Prizer) a humanized monoclonal anti-CCR4 antibody 
which was FDA-approved in August 2018 for the treatment of refractory or relapsed mycosis fungoides 
and Sézary syndrome [15].  
The area of chemokine research has progressed continuously within the last two decades. Although the 
time of the molecular discoveries might be about to end, the need for a more comprehensive 
understanding of the precise roles, mechanisms and biological mediated by chemokines and their 
receptors is unchanged. 
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2.2. Chemokines 
2.2.1. Structure 
Most chemokines are low molecular weight proteins (7-12 kDa) that are synthesized in sequences of 20-
25 amino acids. The characteristic basic tertiary architecture of all chemokine ligands consists on an N-
terminal (signaling domain) followed by an N-loop, a three-stranded β-sheet and a C-terminal helix [16]. 
Biological activity of these proteins can be modified to various levels after being processed at the N-
terminus. In fact, cleavage of chemokine N-terminus is understood as a natural mechanism for 
regulating chemokine function [17]. Although there have been some reports of chemokines that were 
processed at the C-terminus, the cleavage of up to six C-terminal amino acids has not shown to affect 
chemotactic activity [18].  
 
2.2.2. Classification 
Chemokines are grouped into four subfamilies: CXC-, CC-, CX3C- and XC- chemokines based on the 
spacing between their first two cysteine residues (Intr. Fig. 1) [19].  
 
One of the two major subfamilies are the CXC-chemokines (also referred to as α-chemokines), which 
show one non-conserved amino acid between the two cysteines. They are subdivided into two 
categories based on the amino acid sequence located immediately before the first cysteine of the CXC 
motif. “ELR-positive” chemokines have a sequence of glutamic acid-leucine-arginine (ELR for short), 
while chemokines grouped as “ELR-negative” do not show this motif. This subdivision also reflects 
different roles of CXC chemokines as ELR-positive CXC chemokines typically induce the migration of 
neutrophils by interacting with CXCR1 and CXCR2 on their surface while CXC chemokines that lack the 
ELR motif tend to be more chemoattractant for lymphocytes [20,21]. To date 17 different CXC 
chemokines have been described and are named as CXCL1-17. 
 
CC-chemokines are the second major subfamily (also called β-chemokines) and are characterized by the 
lack of an amino acid between the first two cysteines. Most of the members of this group have four 
cysteines before the CC motif (C4-CC) but a few CC-chemokines show six cysteines (6C-CC) [22]. Up to 
27 chemokines have been identified in this group and are named as CCL1-27. 
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C-chemokines only have one cysteine at the N-terminal binding to another close to the C-terminal. 
Unlike the rest of the chemokine subfamilies only possesses one cysteine-cysteine bond. This group is 
only comprised of two members: XCL1 (also named lymphotactin-α) and XCL2 (or lymphotactin-β). 
 
The last group is known as CX3C-chemokines due to the presence of three amino acids between the first 
two cysteines. The sole CX3C-chemokine that has been described is named fractalkine (CX3CL1). 
Fractalkine is unique among chemokines due to its large size (373 amino acids) and the fact that is 
synthesized as a transmembrane protein whit its N-terminal domain facing the extracellular medium 
[23]. 
 
 
Intr. Fig. 1. Chemokines are divided into four subfamilies based on the spacing of amino acids between the first 
two cysteines. From up left, structure of CXC-, CC-, C- and CX3C-chemokines (also known as α-, β-, ɣ- and Δ- 
chemokines). Adapted from Held & Feindt, 2015 [24]. 
 
Aside from the structural characteristics, chemokines can be categorized based on their function [25]. In 
this classification four subgroups can be distinguished: Homeostatic, Inflammatory, Dual-function and 
Plasma chemokines. These categories are not strict and not mutually exclusive [26]. 
 
Homeostatic chemokines are constitutively expressed in lymphoid organs and are related to 
homeostatic trafficking of various lymphocytes and other cells. A good example within this group is 
CXCL12, which is involved in the regulation and migration of bone marrow and thymic progenitor cells 
during immune cell development [27]. On the other hand, inflammatory chemokines are expressed 
under inflammatory conditions and are directly involved in the recruitment of immune cells to inflamed 
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tissues [28]. This group can be further sub-divided into two different categories based on the presence 
of an ELR (Glu-Leu-Arg) motif located before the first cysteine. ELR chemokines are mainly angiogenic 
(like CXCL8) while non-ELR chemokines have angiostatic properties (like CXCL4 or CXCL9) [29].  
 
Some chemokines are involved in both homeostatic and inflammatory processes and are named “dual-
function chemokines” (or dual-chemokines). CCL17 and CCL22 (both ligands of CCR4) constitute a good 
example of this category. This chemokine axis is involved in a series of homeostatic functions, like skin-
homing T-cells, but is also involved in a series of conditions such as asthma and allergic diseases [30]. 
Finally, there is a subgroup of inflammatory chemokines known as “plasma chemokines” which are 
present at high concentrations in serum (like CCL14 and CCL15) [31]. 
 
2.3. Chemokine receptors 
2.3.1. G-protein coupled receptors 
CKRs are members of the seven-transmembrane G-protein-Coupled Receptor family (GPCR). They are 
mostly expressed on migrating cells and bind chemokines in the extracellular medium, triggering 
signaling pathways inside of the cell that usually lead to cell motility [16]. Like all GPCRs, CKRs are 
integrated in the membrane conformed as seven transmembrane helices with the N-terminus facing the 
external part of the cells and the C terminus facing the cytoplasm [32]. After binding to the chemokines, 
CKRs interact with G-proteins. 
 
Heterotrimeric G proteins consist of three subunits α, β and γ. Although the GPCR family comprises 
almost 1000 different proteins, there is a relatively small number of G proteins to trigger a high number 
of intracellular signaling cascades [33]. 35 different genes encoding for G proteins can be found in the 
human genome, 16 of which corresponding to α-subunits, 14 to γ and 5 to β. [34] 
 
 The GPCR transduces the signal to a heterotrimeric G protein, which interchanges the bound GDP or the 
Gα subunit for GTP. This leads to the dissociation of the Gαβγ complex into Gα-GTP and Gβγ and to the 
activation of downstream effector by both subunits. The transduction of the signal ends when the 
intrinsic GTPase activity of the G protein hydrolyzes the GTP to GDP, resulting in the end of the cycle 
[35].  The Gβγ dimer activates a series of signaling cascades that lead eventually to chemotaxis and cell 
adhesion. It interacts with phospholipase C (PLCβ) [36], which leads to the hydrolysis of 
phosphatidylinositol bisphosphate, resulting in the generation of inositol trisphospate (IP3) and 
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diacylglycerol (DAG) [37]. The Gβγ dimer has proven to be critical for chemotaxis, while the Gα subunit 
seems not to be related to this process.  
 
2.3.2. Electrostatic interaction and binding: Glucosamynoglycans (GAGs) 
GAGs are carbohydrate structures that appear bound to protein cores of proteoglycans or attached to 
the extracellular matrix (ECM) of the cells. GAGs contribute to the immobilization of chemokines and the 
formation of gradients that adequately direct the migration of CKR-expressing cells, providing directional 
signals [38].  
 
Chemokine-GAG interactions typically occur through electrostatic interactions of positively charged 
residues with highly sulphated and acidic GAGs [39]. Nevertheless, these interactions appear to be 
complex and recent evidence points to specificity of some chemokines for certain type of GAGs. 
Additionally, other factors like the state of oligomerization, the microenvironment or the 
monomer/dimer configuration of the chemokines can affect these interactions as well [40]. 
 
The immobilization of chemokines by GAGs allows them to act locally rather than in paracrine ways, 
preventing inadequate activation and desensitization of receptors on cells outside of the region of 
interest for a specific physiological situation [41]. GAGs have also been described to promote secretion 
of chemokine ligands from tumor cells and T-cells [42] 
 
2.3.3. Chemokine /Chemokine Receptor binding 
Chemokines are structured in a way that allows maintaining interactions with both GRK and GAGs, and 
the affinities for one or another have to be modulated in a way that enables the transfer of the ligand 
from the GAG to the receptor in the precise moment [39]. 
 
Once in contact with the CKR, the N-terminus from the receptor interacts with the chemokine core 
domain (formally named “chemokine recognition site 1”, CRS1) [43], at the same time that the N-
terminus of the chemokine interacts with the ligand-binding pocket of the CKR (Chemokine recognition 
site 2, or CRS2). This interaction model is referred to as the “two-site model” of receptor activation, and 
CRS1 and CRS2 interactions can be decoupled, at least partially [44,45].  
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Once the chemokine and the CKR are bound together, the complex is rapidly internalized, hampering 
additional interactions of the CKR with other chemokines. This process is named “desensitization” and is 
a key mechanism for regulating the role of CKRs as it inhibits cell migration once leukocytes arrive at 
specific anatomical locations in response to a chemotactic gradient, like for example in the case of 
inflammation. Internalization of certain CKRs can be followed by the expression of different types of 
CKRs. This is called “CKR switching” and is associated with leukocyte function [46,47,48].  
 
2.3.4. Chemokine receptor nomenclature 
CKRs are named and classified based on their chemokine selectivity. Hence, CXC-chemokines bind to 
CXC-receptors. In humans there are up to 19 different CKRs, named CXCR1-6, CCL1-10, XCR1, XCR2 and 
CX3CR1 (Intr. Fig. 2). 
 
2.3.5. Atypical Chemokine Receptors (ACKRs) 
Besides the classical CKRs, a series of so-called “atypical chemokine receptors” (or ACKRs) have been 
described in recent years. The ACKR family comprises four members (named ACKR1-4) and a fifth 
candidate named CCRL2 (CC-receptor like 2) (Intr. Fig. 2). These are seven transmembrane proteins that 
do not signal through G proteins but are able to internalize the chemokine, promote its degradation or 
transport it across the cell [49]. For these reasons ACKRs can influence immune responses in vivo due to 
their ability to arrest chemokines from the local environment [50].  
 
2.3.6. Exclusive receptors 
The majority of the chemokines are able to bind to more than one CKR, and some CKRs have multiple 
ligands. This feature is common among chemokine/CKR pairs involved in inflammation processes. 
Promiscuity is restricted to chemokine class; a CXC receptor will always bind to CXC ligands but never to 
a CC ligand. The specific pathways that a CKR is able to activate depend on which ligand is binding the 
receptor, as well as on the cellular context. This functional selectivity is emerging as a key feature of 
CKRs and up to six CKRs have been described to show this characteristic [51]. On the other hand, some 
CKRs are also able to bind non-chemokine ligands. To quote an example, CXCR2 and CXCR4 have been 
observed to trigger cell migration after binding to macrophage migration inhibitory factor (MIF) [52].  
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Intr. Fig. 2. Human CXC- and CC-chemokines and their binding receptors. Right, GPCR CKRs. Left, ACKRs.  Adapted 
from Bachelerie et al. 2014 [25] 
 
On the other hand, CKRs involved in homeostatic processes bind usually to only one or two ligands that 
only interact with one specific CKR [53]. These “exclusive” chemokine/CKR pairs have been of great 
interest for research. Exclusivity simplifies research efforts since it lacks background effects caused by 
other ligands and eliminates the problem of redundancy in the chemokine system. 
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2.4. Biological functions of Chemokine/CKR interactions 
Shortly after their discovery, chemokines were believed to be merely chemoattractant molecules (and 
were named based on this property). However, over the years it has become increasingly clear that 
chemokines are involved in a wide range or roles and functions. Today, it is assumed that any cell type 
can express chemokines and/or chemokine receptors [54] 
 
2.4.1. Chemoattraction 
Chemokines, alongside with other chemoattractants, drive leucocyte subsets to specific anatomical 
locations under homeostatic conditions as well as in response to inflammation or tissue damage. Upon 
contact with chemoattractants, leucocytes undergo cytoskeleton rearrangement, cell shape changes and 
polarization, initiating cell motility along a concentration gradient [55]. Chemoattractants cooperate 
temporally and spatially. A good example of this phenomenon is the so-called “lipid-cytokine-chemokine 
cascade”, were lipid mediators initiate leucocyte recruitment cascades that induce cytokine production, 
that trigger chemokine expression and release, thus amplifying the signal to other immune cells [56]. In 
this context, sequential chemokine engagement cascades have also been described, such as in 
neutrophil recruitment, for example [57]. In fact, the first observations of a chemokine gradient in vivo 
were performed using a neutrophil migrating model for the study of liver injury [58]. 
 
2.4.2. Other functions of chemokines 
Apart from chemoattraction a wide variety of biological functions and processes may be induced by CKR 
activation on leucocytes, such as proliferation, differentiation, cytokine production, degranulation and 
respiratory burst (Intr. Fig. 3) [59]. Additionally, numerous chemokines have direct antimicrobial activity 
[60]. Besides immune cells, many cell types are able to express CKRs and respond in different ways to 
chemokines, including epithelial cells [61], endothelial cells [62], mesenchymal cells [63] and neurons 
[64]. Various chemokines are reportedly involved in angiogenesis regulation [65] and cancer cells of non-
leukocytic origin can express CKRs and respond to chemokine ligands, triggering invasiveness, spread to 
draining lymph nodes (DLN) and metastasis seeding in distant tissues [66]. 
 
Back to cell motility, chemokines may also control different types of cell movement in addition to 
classical chemotaxis. Examples include haptotaxis, trans-cellular migration and cell adhesion (hence 
stopping cell movement) [67,68].  Furthermore, chemokine gradients can work in a reverse way, causing 
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certain cells to move away from the concentration gradient. This process is called “chemo-repulsion” or 
“chemo-fugetaxis” [69]. 
 
Intr. Fig. 3. Functions of Chemokines and CKRs. Chemokines and their receptors participate in a vast array of 
functions besides cell movement. Scheme adapted from Hughes et al. 2018 [53] 
 
2.4.3. Chemokines in disease 
A well-coordinated function of the immune response is of vital importance. Specific leucocyte subsets 
have to be in the right location at the right moment for their immunological functions to be effective. 
Upon injuries or infection, innate immunity offers a rapid response to kill pathogens, start inflammation 
processes and repairing tissue damage. Adaptive responses and the generation of immune memory 
require precise coordination of leukocyte migratory processes. Without chemokines, this response is 
unsuccessful, immune tolerance is compromised and immunosurveillance fails. Nevertheless, 
chemokine-regulated leucocyte migration may contribute to tissue damage caused by immune 
malfunction or inflammatory processes such as allergies, chronic inflammatory disease, autoimmunity or 
cancer [53]. Moreover, many virus-related diseases involve chemokines. Several viruses carry genes that 
encode inhibitors that alter the function of CKRs of host immune cells as well as chemokine-neutralizing 
proteins of the host [53]. 
Chemokines  
& CKRs 
Cell movement 
Chemotaxis 
Transcelullar  
migration 
Chemokinesis 
Cell adhesion 
Cell arrest 
Chemorepulsio
n 
Haptotaxi
s 
Angiogenesis 
Degranulation 
Differentiation 
Embryonic  
development 
Exocytosis 
Endocytosis 
Immune cell 
developmen
t 
Transcytosis 
Integrin 
Regulation 
Anti-microbial 
activity 
Apoptosis 
Phagocytosis 
Structure/function 
Of cytoskeleton 
Protease secretion 
Introduction 
 
~ 17 ~ 
 
 
There is a long list of diseases reportedly regulated, mediated or caused by chemokines. Through the 
history of chemokine research there has been a series of groundbreaking discoveries implying 
chemokines in human disease. For example the malaria parasite Plasmodium vivax expresses a CKR that 
acts as a transcellular transporter or human chemokines [8]. Chemokines have also been related to HIV 
disease. CCR5 has been widely studied since it was described as a co-receptor for HIV entry on immune 
cells [70]. Moreover, studies found that some chemokines can act as HIV-suppressor factors and are 
implied in person-to-person transmission of this virus [71]. Implication of chemokines and their 
receptors in cancer is well documented in the study of several types of human cancer [72,73,74]. 
 
2.4.4. Chemokines and CKRs as therapeutic targets 
Chemokines and their receptors are attractive targets in translational research since they are involved in 
a great array of pathways and key biological processes, especially immune-related functions. Techniques 
like genetic deletion or antibody neutralization have appeared as efficacious in treating diverse diseases 
in murine models [75]. There is a long list of therapeutics targeting CKRs in late clinical phases of 
development and few have been approved by the FDA [14,76]. Examples of the diseases and 
malignancies targeted include: HIV infection [77], T-cell lymphoma [78], Asthma [79], Multiple sclerosis 
[80], diabetes [81], arthritis [82] and various cancers [83,84].  
 
Nevertheless, many therapeutic have failed during development despite of the strenuous effort of 
chemical and pharmacological industries for various reasons [85]. For instance, one major problem is 
that animal models of inflammatory diseases do not always predict accurately the efficacy in humans 
[86]. Further, the chemokine system is intricate and very redundant. Cells may express several receptors 
with high plasticity over time and most CKR may bind to several ligands and vice versa. Hence blocking 
one CKR may not have the desired effect since other chemokines may fulfill the physiological functions 
assigned to the inhibited receptor [87]. Another consideration is the potential toxicity derived from 
chemokine antagonists. Clinical trials with various CKR antagonists had to be stopped due to side effects 
[88]. 
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2.5. An exclusive pair: The CCR6/CCL20 axis 
One of the few exclusive chemokine/CKR pairs in the chemokine system is conformed by CC-chemokine 
receptor 6 (CCR6) and CC-chemokine ligand 20 (CCL20), referred to as the CCL20/CCR6 axis. CCL20 
reportedly interacts exclusively with its receptor CCR6 in both humans and mice [89]. This chemokine 
axis has been the focus of many studies due to interesting features that make it different from most 
other chemokine axes.  
 
First, supported by unusual genetic and structural characteristics, evidence points to an earlier 
phylogenetic origin CCL20/CCR6 axis in vertebrates than most of the other chemokines [90]. Second, 
unlike the majority of the chemokines, CCL20 displays a dual mode of expression since it is both 
expressed under homeostatic conditions and is inducible upon pro-inflammatory stimuli [91]. These 
facts, together with the wide array of leukocyte subsets that have been reported to express CCR6+ (i.e. 
immature dendritic cells, Th17, T-regulatory and γδ T-cells, B-cells, Macrophages) [108], involve the 
CCR6/CCL20 axis in a great array of different roles and functions. 
 
2.5.1. CCL20 
CCL20 was first described in 1997 by three independent research groups using bioinformatics techniques 
[92]. Due to these simultaneous discoveries, CCL20 was originally named in different ways (Macrophage 
inflammatory protein-3α (MIP-3α) [93], Liver-Activation regulated chemokine (LARC) [94] and Exodus-1 
[95]) until the unified chemokine nomenclature in the year 2000. CCL20 is encoded by the SCYA20 [small 
inducible cytokine family A (Cys–Cys), member 20] gene, which in humans is located in the chromosome 
2q33. The full length human CCL20 gene has 11.826 base pairs that comprise 4 exons and 3 introns 
encoding for a 70 AA protein in its mature form [94]. The CCL20 gene has two variants that differ only in 
three base pairs (Ala-27, GCA) close to the N-terminus. These two isoforms have been named the Ala-27 
and Ser-27 forms of CCL20. Despite of the absence of one aminoacid, studies have revealed that the 
differences between both isoforms in terms of biological activity are minimal [96]. 
 
CCL20 is mainly expressed in organ-associated lymphoid tissues (lungs, lymph nodes, appendix), in the 
liver and by epithelial cells such as keratinocytes in the skin. CCL20 RNA has been found in several organs 
of the digestive system such as the tonsils, esophagus, stomach, small intestine and the appendix [97] 
Presence of CCL20 in these tissues points to its importance in inflammation and immune activation. 
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Additionally, neutrophils, natural killer (NK) cells, Th17 cells, B cells, Dendritic cells, macrophages and a 
variety of other immune cells have been reported to secrete or express CCL20 [98,99,100].  
 
2.5.1.1. Homeostatic expression of CCL20 in the skin 
Under healthy conditions CCL20 can be found in human epidermis at low levels, but can be rapidly 
upregulated upon a bacterial infection or wound generation. In the dermis, CCL20 is rarely expressed and 
infection or injuries do not trigger CCL20 mRNA expression [101].  
 
Shortly after its discovery it was described that CCL20 showed modest anti-microbial activity. Like many 
other chemokines, the accumulation of positively charged residues on one specific point of its structure 
confers the molecule antimicrobial properties [102]. CCL20 has been reported to have anti-microbial 
activity against Escherichia coli, Pseudomonas aeruginosa, Streptococcus pyogenes, Staphylococcus 
aureus and Candida albicans, among other species of bacteria [103]. 
 
2.5.2. CCR6 
CCR6 is a member of the CC-chemokine receptor family, also known as CD196 (Cluster of differentiation 
196). The human CCR6 gene is located in the chromosome 6p27. Full length of CCR6 gene contains 
27.890 bps encoding for a 374 AA protein in its mature form [104].   
 
CCR6 is mainly expressed by leukocytes, therefore can be detected in immune-related tissues and organs 
such as the spleen, bone marrow, tonsils or lymph nodes. However, minor amounts of CCR6 mRNA have 
been detected in other tissues and organs such as kidney, lungs, liver, the gastrointestinal tract or the 
skin [105].  
 
2.5.2.1. CCR6 ligands 
The interaction of CCL20 with CCR6 was confirmed by CCL20 mediated calcium mobilization in cancer 
cells transfected with CCR6 [106]. Upon binding to CCL20, CCR6 activates G-proteins and signals through 
subunits of the Gαi family, triggering a signaling cascade that ends up activating calcium mobilization 
(Intr. Fig. 4) [107].  
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Intr. Fig. 4. CCR6 signaling pathway after CCL20-binding activation. After CCL20 binding, CCR6 activates the release 
of the Gβ and Gɣ G-protein subunits that further activate PLC and Pl3 kinase. Pl3 triggers the conversion of PIP2 to 
PIP3, that activates Ca
+2
 mobilization across IP3. Together with DAG, IP3 activates PKC alongside with additional 
PKCs that end up triggering cell migration. PI3: Phosphoinositide 3 kinase, PLC: Phospholipase Cβ2, DAG: 
diacylglycerol, PIP2: Phosphatidlinositol 4,5-biphosphates, PIP3: Phosphatidlinositol 4,5-bisphosphates 3, IP3: 
Inositol triphosphate, PKC: Protein kinase C, ER: Endoplasmic reticulum. Adapted from Ranasinghe & Eri, 2018 [108] 
 
To date CCL20 is the only known chemokine that can both bind and signal through CCR6. However other 
molecules are capable of binding and activating CCR6, such as anti-microbial peptides named β-defensins 
(Human Beta-defensins, HBDs) have been identified. Further additional chemokines such as CCL5 or 
CCL14 have been shown to be able to partially bind CCR6 without being able to trigger any signal [113].  
 
2.5.2.2. Additional CCR6 binding chemokines 
Shortly after the discovery of CCR6, except for CCL20 most chemokines were excluded as possible 
binding partners for this CC-receptor. One of this early studies showed that the two most similar CC-
ligands to CCL20 (in terms of AA sequence), CCL19 and CCL21 were not able to activate CCR6-transfected 
cells [109]. These first studies contributed to the notion of CCL20 as the unique partner for CCR6. 
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However, some studies have reported that other chemokines could bind to CCR6. For example, CCL5 and 
CCL14 were found to be able to partially desensitize CCR6 in vitro reducing the capability of CCL20 to 
mobilize intracellular calcium [110]. Another chemokine, CCL18 was found to mediate chemotaxis and 
calcium mobilization through CCR6 on human lung fibroblasts [111]. However, CCL18 did not have a 
strong influence in the mobilization of lung-infiltrating CCR6+ T-cells [112]. Taken together, although 
CCL18 can signal through this CKR under certain circumstances, evidence shows that CCR6 is not a 
dominant receptor for CCL18. 
 
Some authors have pointed out the fact that some newly discovered chemokines have not yet been 
tested for their ability to activate CCR6 (such as CCL24 or CCL27), and that most chemokine binding 
studies have been solely based on calcium mobilization assays, which is not always an appropriate 
method to study specific receptor binding and activation processes [113].  
 
On the other hand, although CCR6 expression has been correlated to CCL20, the expression levels of this 
CKR do not necessarily reflect CCL20 activity. For instance, CCR6+ human peripheral blood B-cells have 
been reported to fail to respond to CCL20, as well as to respond to CCL20 without changes in CCR6 
protein or mRNA expression [114]. In another study, T-cells reportedly did not increase their 
responsiveness to CCL20 upon upregulation of CCR6 [115]. 
 
2.5.2.3. β-Defensins 
Defensins are a family of antimicrobial peptides that were first isolated from leucocytes during the 1960s 
and comprise more than 10 different members. They play key roles in innate immunity and are divided 
into two main subfamilies in humans: α- and β-defensins [116]. BDs are small molecules (2-6 kDa) that 
can be classified as well within the broader group of host defense peptides. They are expressed under 
homeostatic conditions but its production can be induced in response to pathogens or pro-inflammatory 
cytokines by epithelial cells of the epidermis of the skin (mainly by keratinocytes) and mucosal tissue of 
the gastrointestinal and respiratory tract [117]. Therefore HBDs are important elements of immunity of 
surface-organs [118] by linking adaptive and immune responses through the modulation of cytokine 
expression and induction of chemotactic migration of various immune cells.  
 
In this context BDs have been observed to recognize, bind and activate CCR6. Concretely, HBD-1, 2 and -
3 were shown to be capable of competing with CCL20 and even displacing it from CCR6, inducing 
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chemotactic-mobilization of CCR6-expressing HEK293 cells, immature DCs and memory T-cells  [119]. 
Other studies have confirmed the fact that HBDs are biologically active ligands for CCR6. HBDs were able 
to recruit DC precursors to neovasculature in tumors through CCR6 [120]. HBD-2 was shown to arrest 
Th17 cells in inflammatory tissues with the same affinity as CCL20 [121]. 
 
However, under certain conditions HBDs do not show as much affinity for CCR6 as CCL20. HBD-2 was 
proven to be 35 times less effective than CCL20 in displacing radio-iodinated CCL20 from CCR6, and 
chemotactic response of CCR6 expressing human spermatozoa was shown to be more efficient in 
response to CCL20 than to HBDs [122]. Additionally, evidence discards implication of HBDs in CCR6 
mediated T and B-cell biology [113]. In fact, involvement of HBDs in CCR6-mediated immuno-modulatory 
activities has been surrounded by controversy, with reports showing contradicting results [123,124]. On 
the other hand HBDs have also been shown to bind and signal through other CKRs such as CXCR4 [125] 
and CCR2 [126]. Despite controversies, it has been demonstrated that HBDs can compete with CCL20 as 
a ligand under proper conditions and are able to induce chemotaxis through CCR6 [113].  
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2.6. CCR6/CCL20 axis in health and disease 
Under healthy conditions, the CCR6/CCL20 axis plays a key role in the homing of immune cells to the 
intestinal epithelium [91]. Studies using CCR6 knock-out (CCR6-/-) mice have found that in the absence of 
this CKR T-cells accumulate in the intestinal mucosa, T-regulatory and B-cell levels within the Peyer’s 
Patches decrease and development of M cells is inhibited [89,127].  
 
The main functions of the CCR6/CCL20 axis in the peripheral steady-state immune system are not 
completely clear. It has been suggested that in the absence of CCR6, other chemokine or chemokine-
independent systems are able to compensate the effects of the lack of this CKR in the basal trafficking 
events of the peripheral immune system [Fehler! Textmarke nicht definiert.]. 
 
2.6.1. CCR6/CCL20 in the immune system 
Numerous leucocyte types have been observed to possess CCR6+ subpopulations. Subsets of lymph node 
resident naïve CD4+ T-cells that start to differentiate into Th1, Th2 and Th17 upon antigen presentation 
upregulate CCR6. While not so widely expressed by Th1/2 cells, a great fraction of Th17 is CCR6+. This 
implies that CCR6 has a key role in organizing adaptive immunity [Fehler! Textmarke nicht definiert.].  
 
Different cytokines such as TGF-β, IL-6, IL-17 or IL-21 can induce CCR6 expression on Th17 cells [128]. 
CCL20 expression can be induced in a series of different T-cell subpopulations by lipopolysaccharide (LPS) 
as well as by some cytokines like IL-1α, TNF-α, IFN-ɣ, IL-1β, IL-17 or IL-21 [129]. IL-23 mediated Th17 
differentiation can induce inflammation and is able to induce the release of CCL20. This CCL20 can create 
a feedback loop (acting in an autocrine and/or paracrine way) that would create a self-perpetuating cycle 
at inflammatory locations [130].  
 
Naïve T-cells can also give raise to Foxp3+ T-regulatory cells that can express CCR6. These immune cells 
are mainly disease suppressive and are able to downregulate inflammatory T-cell proliferation [131]. 
Once T-regs have infiltrated inflammatory sites, these cells can suppress effector T-cell responses by 
releasing TGF-β and IL-10, which downregulate CCL20 expression [132]. 
 
CCR6 has also been related to the biology of γδ-T Cells. Defects in the downregulation of CCR6 in            
γδ-T-Cell precursors can lead to abnormal accumulation of these cells in the fetal thymus as well as a 
decrease in the epidermal tissues [133]. On the other hand, CCR6 is required for the trafficking of mature 
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γδ-T-Cells in the skin [134]. Several B-cell subsets are able to express CCR6. The CCR6/CCL20 axis 
regulates certain B-cell responses [135] and is involved in the basic kinetics of germinal centers (GC) and 
B-cell differentiation [136]. CCR6 can be expressed by naïve and activated B-cells and is necessary for the 
production of high-affinity antibodies [137]. Memory B-Cell precursors have also been shown to express 
CCR6 and it is believed that this can be a hallmark in the differentiation between Memory B-cells and 
Plasma cells (PCs) [138].  
 
Interestingly, the CCR6/CCL20 axis seems to play a role in the coordination of T and B-cells interactions 
during humoral immune response. It has been observed that CCR6+ follicular T-helper cells (Tfh) that 
express CCL20 can retain this chemokine into the cell surface in order to enhance the generation of T-B 
cell conjugates with CCR6+ B-cells [139]. 
 
CCR6 is also expressed in DCs, which play a key role in the initiation of primary immune responses and 
are essential in both innate an adaptive immunity. Recruitment of immature and mature DCs in mucosal 
immunity is CCR6-dependant [104]. CD11b+ and CD11b- DC subtypes found in Peyer’s Patches regulate 
the development of Th2 and Th1 cells respectively and have been found to have CCR6+ subpopulations 
[140].  
 
The CCR6/CCL20 axis has been related to macrophages as well. Tumor associated macrophages (TAMs) 
have been reported to attract CCR6+CD4+ cells (mostly T-regs) through the secretion of CCL20 in some 
malignancies like colorectal cancer [122] or skin cancer [141]. 
 
2.6.2. CCR6/CCL20 as a key player in human diseases 
CCR6 and CCL20 have been reported to be involved in several aspects of human disease, especially in 
auto-inflammatory disorders. The CCR6/CCL20 axis may regulate tolerance and auto-inflammation by 
engaging CCR6-expressing T-regulatory cells and immature DCs. Upon inflammatory conditions however, 
the axis may switch its role and mediate immune defense through activation of CCR6-expressing 
Th1/Th17 cells [142]. When the CCR6/CCL20 axis is disrupted, malfunctions in these systems can occur 
and could lead to adverse immunologic function of several systems that culminate in a number of 
diseases [111].  
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In the recent years the CCR6/CCL20 axis has been linked to various disorders of very different origins. 
Implication of CCR6+ immune cells has been reported for pulmonary sarcoidosis, where CCL20 
expressing lung interstitial tissue attracted CCR6+ T-cells, DCs and macrophages [142]. Looking at renal 
disorders, CCR6 deficiency in nephritic mice caused an imbalance of T-regs/Th17 cells and caused renal 
damage and high mortality compared to controls [143]. Furthermore, CCR6 has also been studied in 
autoimmune renal disease and the prevention of allograft rejection in kidney transplantation [144].  In 
the liver, intrahepatic increase of CCR6 and CCL20 was correlated with chronic liver disease [145] and it 
has been reported that CCR6-deficient mice are not able to recruit IL-17-expressing ɣδ T-cells towards 
inflammation sites in the liver, resulting in acute liver fibrosis [146]. CCR6 and CCL20 have also been 
related to brain disorders. Transfer of CCR6- Th17 cells significantly inhibited experimental autoimmune 
encephalomyelitis [147].  
 
Another study found a correlation between the amount of brain-infiltrating CCR6+ ɣδ T-cells and cerebral 
ischemia related tissue damage  [148]. Neutralization of CCL20 resulted in improved clinical signs on an 
experimental model for dry eye disease, by reducing the amount of Th17 infiltrating cells into the ocular 
surface [149]. Some studies have also focused on the role of this chemokine axis in clinical reproduction 
and contraception. Capacitated sperm exhibits a directional movement towards CCL20, and under 
homeostatic conditions sperm motility is known to be related with CCR6/CCL20 interactions in the 
reproductive tracts of both sexes [150]. In the gut the disruption of the CCR6/CCL20 axis is a contributing 
factor responsible for inflammatory disorders in the gastrointestinal tract [151]. CCR6 and CCL20 have 
been also involved in obesity and diabetes. Inflammation of the adipose tissue driven by this axis has 
been related to obesity. In this study, CCL20 overexpression in adipocytes had a positive correlation with 
the body mass index (BMI) [152]. The disruption of the CCR6/CCL20 axis in the pancreas has been 
suggested as a therapeutic mechanism to hamper inflammation-triggered dysfunction observed in both 
obese and diabetic individuals [153]. Implications of this chemokine axis have also been observed in HIV 
studies. CCR6 has been shown to act as a receptor for HIV invading T-helper cell subsets alongside with 
CXCR4 and CCR5, although with lower affinity [154]. 
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2.6.2.1. CCR6/CCL20 in inflammatory skin diseases 
Since CCR6 is expressed by leukocyte subsets that drive inflammation in the skin, a large series of studies 
have focused on the contribution of the CCR6/CCL20 axis in various acute and chronic inflammatory skin 
diseases. 
 
For instance, reduced CCL20 production caused by keratinocyte deficiency in atopic dermatitis (AD) 
results in a decrease of CCR6+ leucocytes and exposes patients to bacterial and viral infections that can 
lead to the aggravation of eczemas. For instance, keratinocyte deficiency caused by a skin disorder 
named atopic dermatitis (AD) results in reduced CCL20 production, which leads to CCR6 downregulation 
that exposes patients to viral infections that may lead to eczemas. In fact, AD patients are more likely to 
have small mutations in the CCL20 gene, displaying the same phenotype [155]. Another study found that 
CCR6- subpopulations of T-regs cells with high expression of CD25 would acquire Th2-like properties in 
AD lesions [156].  
 
CCR6+ immune cells have also been reported to play key roles in contact dermatitis. CCR6+ Th17 and 
Th22 cells were found to infiltrate inflamed skin regions in a study model for allergic contact dermatitis 
(ACD) [157]. In another study, researchers found that CCR6-/- mice showed altered responses in contact 
hypersensitivity (CHS) and delayed-type hypersensitivity (DTH) suggesting a defect in the activation and 
migration of CD4+CCR6+ T-cells [Fehler! Textmarke nicht definiert.]. Subsets of NK cells expressing a 
specific set of chemokine receptors including CCR6 have also been found to contribute to accumulate in 
ACD [158]. Additionally, increased amounts of CCL20 have been found in skin samples from patients with 
AD when compared to healthy controls [159]. 
 
CCR6 has been linked to urticarial as well. In a study about chronic idiopathic urticarial (CIU), peripheral 
blood mononuclear cells (PBMCs) from patients with CIU had increased levels of CCR6 mRNA [160]. 
However, the precise role of CCR6 in this disease still needs further research.  
 
In psoriasis, a common chronic inflammatory autoimmune skin disease, CCR6 and CCL20 are highly 
expressed in skin lesions and immunological activation is mainly driven by CCR6+ Th17 cells [161]. 
Injection of IL-23 in the skin of mice results in psoriasiform dermatitis, resembling human psoriasis. It has 
been reported that CCR6-deficient mice fail to develop psoriasiform lesions in the skin after IL-23 
intradermal injections, which promotes accumulation and proliferation of Th17 cells. Furthermore, 
keratinocyte derived CCL20 contributed to recruit additional CCR6+ expressing T-cells towards psoriatic-
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like lesions [162,163]. Therefore inhibition of CCR6 has been suggested as a possible therapeutic 
treatment, in particular in addition to modern antibody therapies effectively targeting Th17-mediated 
skin inflammation in psoriasis [164]. 
 
In recent years there have been some approaches in this field. Using narrow band ultraviolet B-light (NB-
UVB) phototherapy researchers were able to decrease CCR6 expression in PBMCs from psoriatic patients 
[165]. More recently, an approach using a modified CCL20 variant that could bind CCR6 but did not 
trigger a strong chemotactic response could prevent psoriatic inflammation in an IL-23 dependent mouse 
model for psoriasis [163]. Several additional research groups are also experimenting with different 
compounds that downregulate CCL20 expression, alone or together with other cytokines [166,167,168]. 
 
Besides Th17 cells, additional CCR6-expressing immune cell subsets have also been linked to psoriasis. 
These include γδ T cells [161]; Th22 cells, which secrete cytokines (IL-22, IL-13 and TNF-α) that contribute 
to the pathogenesis of psoriatic lesions [169]; and neutrophils. Neutrophils have been recently suggested 
to be the cause of CCR6+ T-cell migration towards psoriatic lesions. According to this, epidermis 
infiltrating neutrophils secrete IL-17A, which triggers IL-23 and CCL20 expression by keratinocytes, thus 
attracting CCR6+ Th17 cells and enhancing proliferation of this leucocyte subset [170].  
 
2.6.3. CCR6/CCL20 in cancer  
Cancer initiation, growth and metastasis are part of a sequential and selective process regulated by local 
tissue conditions, growth factors, cell-adhesion molecules and chemokines. In this context, chemokines 
can control the progression and outcome of cancer through different mechanisms.  
 
For instance, chemokines drive the migration of immune cells towards tumors, which may result in anti-
tumor immune responses or enhanced tumor growth [171]. Chemokines are also able to regulate 
angiogenesis through the interaction with endothelial cells expressing certain CKRs [172]. Through direct 
interaction with tumor cells, proliferation and apoptosis can be directly controlled by chemokines as well 
[173].  
 
Cancer cells may use chemokines during metastatic processes to directly invade the lymphatic system 
and spread through the blood, as well as to settle and develop in a new location [174]. The fact that 
tumor cells could use CKRs to direct organ-specific tumor metastasis has attracted the attention of the 
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scientific community. Tumor cell surface signals, together with chemotactic gradients could allow cancer 
cells to migrate towards specific metastatic destinations [175]. 
 
In this context, CCR6 and CCL20 have been reported to be involved at different stages of tumor 
progression in cancer. In pancreatic carcinoma, stimulation of CCR6+ tumor cells with CCL20 triggered 
tumor cell proliferation, migration and invasion of tissues, pointing to a role of mechanisms used by 
autocrine and paracrine secreted CCL20 [176]. In colorectal cancer, CCL20 mediated macrophage 
recruitment into the intestine was reported to cause spontaneous intestinal tumorigenesis [177]. CCR6 
and CCL20 can also affect tumor progression in coordination with other chemokines, like in ovarian 
cancer, where changes in the chemokine network involving CCL20- and CXCR2- related pathways result 
in enhanced tumor development [178]. 
 
2.6.3.1. CCR6/CCL20 in skin cancer  
In skin cancer, CCR6 has been suggested to be involved in the regulation of metastasis alongside with 
other CKRs. In squamous cell carcinoma (SCC), downregulation of CCR6 followed by upregulation of CCR7 
and CXCR4 promoted tumor migration to regional lymph nodes [179]. Downregulation of CCR6 followed 
by expression of CCR2 in γδ T-cells was shown to be of high importance in the trafficking of these cells 
towards the dermis in human papillomavirus-associated uterine cervical SCC [180]. Similar mechanisms 
have been observed for metastasis of basal cell carcinoma (BCC) tumors [181].  
 
A few studies have focused on the involvement of CCR6 and CCL20 in the progression of cutaneous T-cell 
lymphoma (CTCL). Advanced CTCL showed high expression of IL-22, CCR6 and CCL20, but not of IL-17 
[182]. In fact CTCL produced IL-22 was found trigger CCL20 by keratinocytes, which attracted CCR6+ 
dendritic cells that initiated inflammatory responses in the skin [183]. In addition, upregulation of CCR6 
and CCL20 enhanced metastatic processes in CTCL. Considering this data, the inhibition of the 
CCR6/CCL20 axis has been suggested as a therapeutic strategy for advanced CTCL [184]. 
 
Several groups have studied the implication of the CCR6/CCL20 axis in melanoma but the precise 
functional contribution to this malignancy remains controversial (See 2.9)  
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2.7. Skin Cancer 
Skin cancer is the most common type of neoplasia worldwide, with a major preponderance among the 
Caucasian population and higher incidence in regions with intense solar exposure. 35-45% of all cancers 
among the Caucasian population are a type of skin cancer [185]. This value is lower among Hispanic (4-
5%), Asian (2-4%) and African populations (1-2%) [186]. It is also related to professions with longer 
exposure to ultraviolet radiations (UV). The incidence among fair-skinned populations has keep 
increasing during the last 30 years, while in darker pigmented populations has remained more or less 
stable, partially due to UV-photo-protection provided by higher amounts of melanin and different 
structures of the melanosomes [187, 188].  
 
Skin cancer is commonly divided into melanomas and non-melanoma skin cancer (NMSC). Every year two 
million new cases of NMSC are diagnosed in Europe and the United States [189,190]. These carcinomas 
can be divided into two main groups: Basal Cell Carcinoma (BCC) and SCC. There are other types of 
cutaneous tumors (although much less frequent that BCCs and SCCs) such as adnexal tumors, Merkel cell 
carcinomas, Darier-Ferrand tumors, and B and T cutaneous lymphomas [192]. 
 
The major environmental risk factor for BCC and SCC is UV radiation. Therefore it appears predominantly 
in photo-exposed areas like the head and neck (90% of the cases). Additional risk factors include radio-
dermatitis, burn scars, chronic ulcers, immunosuppression and hereditary disorders such as 
occulocutaneous albinism and xeroderma pigmentosum [186]. 
 
BCC and SCC are the most common types of cutaneous tumors. BCC has an incidence of approximately 
150-744 cases for every 100.000 individuals in Caucasian populations, whereas SCC appears with a 
frequency of 42-132 cases for every 100.000 Caucasians. SCC is the cause of death in 75% of all the 
individuals with non-melanoma cutaneous tumors, although it only represents 20% of non-melanoma 
cutaneous tumors [191]. 
 
Since not all types of skin cancers, in particular (NMSCs) such as SCC and BCC, are routinely registered in 
national tumor registries and in most of the cases are not a cause of death, the real incidence and 
mortality rates are difficult to acknowledge. Nevertheless these cases should lead to an underestimation 
of skin cancer incidences worldwide and as skin cancer constitutes a major economic and health burden 
in terms of diagnosis, therapies and follow-ups in the field of oncological pathology [192]. 
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2.7.1. Melanoma 
Melanoma represents the sixth most frequent neoplasia among men and the seventh among women 
[186]. The incidence of melanoma in Europe and the US has been increasing between 3-7% annually for 
the past years and is one of the tumor types with the highest mortality rates [193].  
 
Nevertheless the increase in the incidence seems to be partially related to more awareness and 
prevention among the population and early diagnosis, resulting in higher detection rates of melanoma 
without a parallel increase in the mortality rate [194]. Improvements in clinical diagnosis and surgical 
techniques, together with more accurate classification guidelines of melanoma have contributed to 
these advances as well, and melanoma patients with high risk of relapse are identified with better 
precision [189]. 
 
While early tumors may be cured by surgical excision alone, metastatic and locally advanced disease is a 
major concern in melanoma patients and has been associated with poor prognosis and low survival 
rates.  
 
2.7.1.1. Epidemiology, risk factors and prognosis 
Melanoma is a malignancy that develops from the pigment containing cells known as melanocytes that 
start to proliferate uncontrollably for various reasons [192]. Melanoma can be categorized into two 
different subgroups based on etiopathogenetic differences: On one hand most common melanomas 
show a superficial diffusion arising de novo or from a pre-existing nevus. Most melanomas grow primarily 
in an horizontal manner that may turn into a vertical growth pattern over time, gaining metastatic 
potential. On the other hand some melanomas arise de novo alongside with a fast vertical growth, 
aggressive biological behavior and high metastatic potential shortly after its appearance. The pathogenic 
mechanisms of this less frequent form of melanoma are yet to be elucidated [195].  
 
Slow evolution melanomas appear to be related with the exposure to UV radiation, with risk factors 
including accumulated dose of radiation, type of exposure (intermittent or continuous) and sunburn. Sun 
exposure in genetically susceptible individuals can induce melanocytic naevi (or moles), high frequencies 
of which imply increased risk for melanoma development. Having ≥100 melanocytic naevi increases the 
risk for lifelong melanoma development in seven orders of magnitude. Asymmetric and irregular shapes 
of naevi are an additional risk factor [196].  
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Melanoma is more common among individuals from ages between 40 to 60 years but it also affects 
those in adolescence and at late stages of life (80 years or more). The average age at melanoma 
diagnosis is 57 years [197]. In adults between 20 to 29 years, melanoma is one of the most common 
types of cancer [198]. Melanoma appears more frequently in the back for male individuals and in the 
legs for females [199].  
 
The process of metastasis is commonly believed to be a late event during tumor development. However, 
metastasis can initiate at any phase of tumor progression, even during primary tumor formation, and is 
influenced by many factors: The host immune response, the tumor microenvironment, and most 
importantly, the capacity of the metastatic cell to generate a new tumor in a new location [200,201,202]. 
The mechanisms that underlie these processes are still to be precisely elucidated. The genetic and 
epigenetic backgrounds of tumor cells could explain the differences in metastatic potential, and this 
should be reflected when comparing primary and metastatic tumors of the same patient. Evidence 
points to considerable functional heterogeneity within melanoma tumors, since it seems that certain 
tumor cell subpopulations have higher potential to repopulate the tumor mass and resist certain stress 
factors (like hypoxia or drug toxicity) [203,204]. 
 
Metastasis of melanoma is associated with poor prognosis. Nevertheless this depends on the specific 
location of distant metastases. The metastases located in the skin, subcutaneous tissues and lymph 
nodes are associated with longer survival than visceral metastases [205]. 
 
Superficial spreading melanoma comprises almost 70% of all melanoma-diagnosed cases. There are 
other types of melanoma that differ from superficial spreading melanoma in terms of morphology, radial 
growth, metastatic potential and anatomical locations [206]. These melanomas represent the remaining 
30% of cases and include: Lentigo melanoma, Acral lentiginous melanoma, Nodular melanoma, 
Amelanotic melanoma and uveal melanoma [192]. 
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2.7.1.2. Melanoma pathogenesis 
2.7.1.2.1. Molecular pathogenesis 
A complex interaction between exogenous and endogenous events is required for the transformation of 
melanocytes into melanoma. The genetic basis of melanoma tumors has been widely investigated in 
recent years [207]. 
 
The first genetic data from melanoma tumors was obtained from patients who had relatives also 
affected by melanoma. Familiar background is reported in close to 10% of all melanoma patients. From 
this cases, 40% carry high-risk germline mutations in the cyclin-dependent kinase inhibitor 2A (CDKN2A) 
gene [208,209]. CDKN2A encodes two tumor suppressor proteins, p16INK4A and p14ARF, through 
alternative promoters and alternative splicing. Protein p16INK4A plays a maintenance role in cell-cycle 
control by the activation of a signal cascade that inactivates the retinoblastoma-associated protein (RB), 
while p14ARF controls de degradation of cellular tumor antigen p53 (encoded by the retinoblastoma gene 
TP53) through a series of intermediaries [210]. Therefore, mutations in CDKN2A induce G1-S cell-cycle 
transition due to the loss of two key regulators of cellular homeostasis, RB and p53 [211]. Germline 
mutations in the gene of the p16INK4A downstream effector cyclin-dependent kinase 4 (CDK4) have also 
been found in melanoma-prone families [212]. Other less common germline mutations have been 
reported (for example, in BAP1 [213] or POT1 [214] genes) but overall, more than half of all familial 
melanomas have an unknown genetic basis [215]. 
 
Sporadic melanomas constitute around 90% of all melanomas and are usually driven by low/moderate 
risk alleles that possess high prevalence and low penetrance, indicating that environmental factors are 
likely to be the main cause of malignant transformation [216,217]. Various population studies have 
related the melanocortin 1 receptor gene (MC1R), which has more than 100 allelic variants, with red 
hair, low tanning capability and higher melanoma risk [218]. The MCR1 gene controls the regulator of 
pigmentation encoded by the gene MITF (micropthalmia-associated transcription factor), and therefore 
the production of melanine. Mutations in MCR1 can induce different levels of UV light highly protective 
eumelanine or less-protective pheomelanin [219]. Germline polymorphisms have also been reported in 
other pigmentation-related genes such as ASIP, OCA2, PAX3 or SOX10 [220]. 
 
Various reports cast doubt the hypothesis that melanoma is only caused by UV directed mutations. A 
good example of this is that primary melanomas can arise in non-sun exposed skin or in internal organs 
Introduction 
 
~ 33 ~ 
 
[215]. The signaling cascade with the highest oncogenic and therapeutic relevance in melanoma is the 
one controlled by the mitogen-activated protein kinase (MAPK), and most of the mutations found in this 
gene are not related to direct UV damage [221]. Other common mutations that are not caused by UV-
light are NRASQ61L and NRASQ61R (detectable in approximately 15-20% of melanomas) [207]. Nevertheless 
the causal role of UV light in these mutations cannot be completely excluded, since indirect effects like 
the generation of free radicals resulting from the interaction of UV light with melanin can act as 
mutagens that indirectly cause genetic mutations [222]. 
 
However mutations in single genes are generally not sufficient to result in melanoma development. The 
most accepted hypothesis is that mutations in these genes constitute the first steps of the 
transformation of melanocytes, which require further mutations in additional genes that would 
eventually lead to the development of melanoma [223]. In fact more than 80% of nevi carry BRAF and 
NRAS mutations [224].  
 
2.7.1.2.2. Molecular classification of melanoma 
The recent development of targeted therapies to treat advanced-melanoma with activating driving 
mutations has been significantly successful [225]. Therefore the scientific community has been trying to 
generate a framework to be used for personalized therapies in patients with melanoma [226]. In this 
context, melanomas can be classified into 4 different genomic groups (or subtypes) based on significantly 
mutated genes (SMGs) that are directly related to the MAPK pathway. 
 
The main genomic subtype is the one characterized by hot-spot mutations in the BRAF gene. 
Approximately 50% of all advanced melanomas carry a mutation in this gene (with V600E being the most 
common one) [227]. Most melanomas from this category harbor UV-caused mutations and are more 
frequent among younger patients [226]. The RAS subtype is the second largest group (with a frequency 
of approx. 25%), and includes mutations in the 3 genes belonging to this superfamily (N-, K- and H-RAS). 
Certain hot-spot NRAS mutations are anti-correlated with some specific BRAF mutations [228].  The third 
most frequent group is the NF1, with close to 15% of all cases). Most of the melanomas with these 
mutations occur in sun-exposed skin and are more common in older individuals [229]. A fourth group is 
named as the Triple Wild-Type (TWT) subtype, which is more heterogeneous and is characterized by a 
lack of hot-spot BRAF, RAS or NF1 mutations. Most of these melanomas (around 70%) do not harbor UV-
caused mutations [226]. 
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2.7.1.3. Melanoma interactions with the microenvironment 
During the development of melanoma, cancer cells interact with different cellular components within 
the tumor microenvironment. On one hand there are interactions between melanoma cells and different 
components from the stroma, such as fibroblasts, endothelial cells or infiltrating immune cells [230]; and 
on the other hand tumor cells interact with tumor cells from different sub-compartments within the 
tumor, that are characterized by the differences in the access to oxygen and nutrients [231]. 
 
Interactions between tumor cells and these cellular components can occur at different molecular levels, 
mainly via cell-cell contact or through the secretion of cytokines and growth factors [232]. These 
molecules can remodel the microenvironment by affecting tumor progression, growth and metastasis, as 
well as other processes such as angiogenesis or tumor cell apoptosis [233]. Differential secretion of 
certain chemokines can attract specific immune cell subsets, which in turn secrete more molecular 
signals that affect the final outcome of melanoma tumors [234]. 
 
2.7.1.3.1. Tumor infiltrating leucocytes (TILs) 
Advanced melanoma tumors contain considerable amounts of immune cells. The contribution of the 
immune response to the final outcome of malignant melanoma tumors depends on various factors and 
the prognostic value of tumor infiltrating leucocytes (TILs) has been a matter of controversy in the field 
of immunotherapy  [235]. It has been suggested that the reason behind the contradicting data on the 
prognostic impact of TILs in melanoma is that the effect of the immune infiltrate may be more 
pronounced in advance-stage melanoma compared to early stage melanoma [236]. 
 
Several immune cell subsets have been reported to infiltrate melanoma tumors. One of the first immune 
cell types that can be detected at early stages of tumor growth are dendritic cells (DCs). These antigen 
presenting cells (APCs) process tumor antigens into peptides that will be later presented trough the 
mayor histocompatibility complex (MHC) to effector cells [237]. Signals from the tumor 
microenvironment stimulate Toll-like receptors (TLRs) that trigger migration of the DCS towards regional 
lymph nodes and present the tumor antigens through the MHC to T-cells (T-cell priming) [238].  
 
Once T-cells have been activated, they can migrate towards the tumor microenvironment. This process is 
referred to as “homing” of T-cells. This process is regulated through the expression of cell adhesion 
molecules by the T-cells as well as chemokines secreted by tumor cells. Once they have infiltrated, T-cells 
recognize melanoma cells and initiate a cytotoxic signal that can kill the tumor cells [239]. 
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The presence of T-cells (CD4+ and CD8+) has been widely demonstrated to be a good prognostic factor in 
different types of cancer [240,241]. However, their role in melanoma is not completely clear. While some 
studies have found a positive correlation between the presence of CD4+ and CD8+ T-cells within the 
tumor and good tumor prognosis, others studies found no association between the overall infiltrating 
CD3+ T-cells and better melanoma outcome [236]. It has been suggested that these differences may be 
originated by methodological differences on the analysis of the TILS. For instance, some groups 
evaluated the infiltrate of the whole tumor [242], while others restricted the analysis of TILs exclusively 
to specific tumoral regions [243]. The state of activation of the T-cells has been another source of 
controversy, since not all the studies have reported the proportion of activated T-cells found in the 
samples. T-cells found within the tumor are frequently defective and show depressed proliferation 
capability or hampered cytotoxic activity [244]. Therefore it is recommended to characterize the 
activation state of T-cells in addition to a quantitative determination. In general, high peritumoral 
density of activated T-cells is associated with a good prognosis [245]. 
 
Among CD4+ T-cells, FOXP3+ T-regulatory cells (T-regs) can also be found within melanoma tumors and 
are implicated in the inhibition of antitumor immune response [246]. Nevertheless the presence of this 
immune cell type has also been a matter of controversy. While some studies reported a correlation 
between the amount of T-regs within the tumor and higher survival [247], most of the reports have 
found no association between the density of this immune cell subset and melanoma outcome [248]. 
 
The density of B-cells within melanoma tumors is relatively low and their contribution to melanoma 
outcome has been a matter of debate as well. On one hand B-cells can promote tumor growth through 
the secretion of certain antibodies and inhibitory factors, and on the other hand they can work as 
effective APCs activating effector T-cells [236]. Discrepancies regarding the pro- or anti-tumorigenic role 
of B-cells have been related to the high diversity of functions that these cells carry [249]. Despite these 
controversies, studies that analyzed the density of B-cells alongside with activated T-cells have been 
more consistent. High B-cell infiltration together with activated T-cells provides higher survival chances 
[250]. 
 
Macrophages can also be found at high numbers within melanoma tumors and play a key role in tumor-
associated inflammation. TAMs can serve as APCs can stimulate T-cell responses as well as secrete toxic 
substances that contribute to antitumor cytotoxic activity [251]. Tumor infiltrating macrophages can also 
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secrete chemokines that attract additional immune cells towards the tumor site that further enhance 
antitumor immune responses [141]. Nevertheless, macrophages can also contribute to tumor 
progression through the stimulation of angiogenesis or enhancing tumor invasion and metastasis [252]. 
 
2.7.1.3.2. Immune escape in melanoma 
Antitumor immune surveillance cannot always be effective. For instance, high numbers of incompletely 
matured DCs may lead to tolerance instead of generating a proper antitumor immune response [253]. 
Since tumor cells have high mutation rates, even in the event of proper T-cell activation, mutations in 
melanoma cells can lead to the loss of the old and the generation of new antigens that cannot be longer 
recognized by the T-cells [254]. 
 
Tumor progression can occur even in the presence of a strong anti-melanoma immune response. Once 
tumor growth has started, cancer cells are able to modulate the immune response through several 
different mechanisms [Fehler! Textmarke nicht definiert.]. For instance, even upon proper activation of 
T-cells, the absence of the proper chemoattractants at the tumor microenvironment can inhibit homing 
of these leucocytes to the tumor. Melanoma tumors are also able to hamper the immune response by 
secreting suppressor factors [244].   
 
Another of these mechanisms is to encompass immune-checkpoint pathways that are responsible for 
self-tolerance. For example, tumor cells can limit T cell effector activity by the expression of programmed 
death ligands 1 (PDL1) and 2 (PDL2), which are the ligands of the surface receptor programmed cell dead 
protein 1 (PD-1). In addition, other T-cells, B-cells and NK cells are also affected since they also express 
PD-1. Another example of how tumor cells can hamper immune response is by the expression of the 
cytotoxic T lymphocyte protein 4 (CTLA4), which mitigates the magnitude of the initial T-cell activation by 
dendritic cells within the lymph nodes [255]. Other immunosuppressive mechanisms are the 
downregulation of tumor-associated antigens or the secretion of inhibitory factors like transforming 
growth factor-β (TGF-β) or IL-10 [256]. 
 
 
2.7.1.4. Cytokines and chemokines in the tumor microenvironment 
Chemokines within the tumor microenvironment can profoundly influence tumor cells as well as other 
components of the stroma, thus having an important impact on tumor biology. Melanoma cells have 
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been reported to express several CKRs (including CXCR1, CXCR2, CXCR3, CXCR4, CXCR6, CXCR7, CCR1, 
CCR2, CCR5, CCR6, CCR7, CCR9 and CCR10, among others) and to produce chemokines (such as CXCL1, 
CXCL2, CXCL6, CXCL7, CXCL8, CXCL10, CCL2, CCL5 and CCL20) that are able to act in paracrine and 
autocrine ways [257].  
 
Together with growth factors, proteases and other cytokines, tumor cells can use chemokines to 
generate chronic inflammatory conditions that lead to the generation of an immunosuppressive 
environment [258]. Through this type of mechanism melanoma cells can influence fibroblast and 
macrophages to acquire pro-tumorigenic functions [259]. Additionally, while the tumor is growing, 
mobilization of myeloid-derived suppressor cells (MDSCs) and T-regs towards the tumor site can be 
enhanced by tumor-derived chemokines such as CXCL5 [260]. Melanoma derived chemokines can 
further induce T-regulatory cells to express immunosuppressive cytokines such as IL-10 and TGF-β that 
can hamper the function of anti-tumor T-cells [261]. 
 
The precise role of a specific chemokine CKR pair in the immune control of melanoma can be difficult to 
elucidate when it is not studied in a greater context. For instance, CXCL10 stimulates Th1 cells, which 
release interferon-ɣ (IFN-ɣ) that contributes to melanoma regression [262] while CXCL4 activates Th2 
cells, which release certain interleukins (like IL-4 or IL-13) that facilitate tumor progression [263]. Both 
CXCL10 and CXCL4 signal through the same CKR, named CXCR3 [264].  On the other hand, it has been 
reported that inhibition of CCL27 contributes to immune evasion and tumor progression [265]. However, 
another study found that when B16 melanoma cells overexpress its receptor CCR10 they are more 
resistant and are more protected against Fas-mediated apoptosis [266].  
 
Melanoma derived CXCL12 has also been observed to play dual roles in anti-tumoral immune responses. 
On one hand CXCL12 has been observed to reduce the immune response by attracting CXCR4+ DC 
precursors that alter antigen-presenting mechanisms of other DCs [267]. However, it has been reported 
that CXCL12-expressing B16 cells induce specific memory responses to the tumor [268] and that CXCL12 
expression attracts CXCR4+ T-cells which facilitate tumor regression [269]. 
 
Nevertheless, there are numerous examples where consistent observations have allowed clarifying the 
precise role of these compounds. One of these examples is CCL21, one of the ligands for CCR7. Under 
normal conditions, CCL21 is produced in the lymph node and is able to attract both CCR7+ APCs and 
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CCR7+ melanoma cells. It has been observed that melanoma tumor cells are able to express CCL21 and 
CCL19 (also a ligand for CCR7) creating an autocrine effect referred to as “autologous chemotaxis”, which 
induces tumor cell migration towards the lymph node [270]. In another study, authors reported that 
expression of CCL21 by B16 melanoma cells caused larger tumors despite attracting greater amounts of 
leukocytes and APCs towards the tumor site. These observations could not be reproduced using 
immune-deficient mice, pointing to the immune system as the responsible for this outcome. Melanoma 
tumors expressing high amounts of CCL21 attract more T-reg cells that contribute to immune tolerance 
and therefore progression of the tumor, while low expression of this chemokine within the tumors 
results in increased migration of cytotoxic T-cells that contribute to tumor regression [271]. 
 
Chemokines can influence tumor growth by the modulation of other processes such as angiogenesis. A 
series of melanoma-produced chemokines can bind to CKRs expressed by endothelial cells triggering 
angiogenic processes. In general, ELR+ CXC chemokines (like CXCL1-3, CXCL5 or CXCL8) are more 
angiogenic while those chemokines lacking the ELR motif (like CXCL4, CXCL9 or CXCL10) promote 
angiostasis [20]. Knocking down angiogenic chemokines can lead to a reduction in tumor growth, 
migration and invasion [272]. CXCL6 and CXCL8 have been observed to promote angiogenesis through 
the recruitment of neutrophils that trigger the degradation of the matrix [273]. On the other hand, 
upregulation of angiostatic chemokines like CXCL4 can hamper the vascularization of growing tumors 
slowing down tumor growth [274]. Therefore, an imbalance between the proportion of angiogenic and 
angiostatic chemokines can determine the outcome of a melanoma tumor.   
 
Chemokines and their receptors may also play a key role in metastatic spread of melanoma [275]. 
Melanoma cells are able to overexpress CXCR4, CCR7 and CCR10. Since CXCL12, the ligand for CXCR4, is 
mostly expressed in tissues like the lymph nodes, liver, lung and bone marrow, it has been suggested 
that CXCR4 be a factor of selective spread of metastatic cells towards this anatomical locations  [276]. As 
a matter of fact, CXCR4 might contribute to tumor spread towards these tissues [277] and tumor cell 
subpopulations of various types of cancer express this receptor [278]. In another study, researchers 
observed a 10-fold greater capacity for metastasis of B16 murine melanoma cells to the lung when they 
were transfected with CXCR4 [198]. Additionally, CXCL12 has been reported to promote tumor growth by 
angiogenic properties [279]. 
 
In the case of CCR7, its ligands (CCL19 and CCL21) are mostly expressed in lymph nodes and lymph 
vessels, and interactions with their receptor have been associated in the development of lymph-node 
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metastasis in mice [280]. On the other hand, CCR10 is suspected to the pathogenesis of skin metastases, 
since its ligand (CCL27) is mainly expressed in the basal cells of the epidermis [276].  
 
In addition to CKR expression, the secretion of chemokines by melanoma cells has been suggested to be 
part of a coordinated mechanism that generates circuits or autocrine loops in the tumor cells 
themselves. For example, some chemokine ligand/receptor pairs such as CXCL12/CXCR4 and CCL21/CCR7 
can act in an autocrine way stimulating the proliferative and invasive capacity as well as the metastatic 
potential of melanoma tumor cells [281,282].  
 
Finally, chemokines have also been linked to tumor initiation and drug resistance since they control key 
signaling pathways of cancer stem cells (CSCs). Although under normal conditions CSCs remain 
quiescent, they can start to proliferate upon certain changes at the microenvironment [283]. It has been 
reported that CXCL12 is able to trigger the migration of dormant CSCs into the blood stream [284]. Some 
CKRs have been linked to CSC chemotaxis such as CXCR1 [285] or CXCR4 [286]. 
 
2.7.2. Novel therapeutic options for advanced melanoma 
In recent years the research of mutations responsible of tumorigenesis and immune-evasion 
mechanisms from melanoma tumors has contributed to the generation of effective treatments that have 
improved the overall survival (OS) in late stage melanoma patients [287].  
 
One of the most success full therapies is the use of immune-checkpoint inhibitors. Among the current 
first-line immunotherapies, drugs such as Ipilimumab or Nivolumab are being widely used and can 
improve the OS of advanced melanoma patients [287]. These compounds are monoclonal antibodies 
that block CTLA-4 (Ipilimumab) or PD-1 (Nivolumab), altering T-cell activation and effector phase 
respectively [288,289]. Current studies have focus on the beneficial effects of therapies that combine 
two or more of these components in order to improve the efficiency of these treatments [290]. 
 
Another current strategy for the treatment of advanced melanoma is the use of targeted therapies. 
These consist in the blockade of signaling pathways from mutated genes such as BRAF or MAK. One 
example is the use of tyrosine kinase inhibitors (TKIs) of the BRAF kinase. Since BRAFV600 mutations are 
the most common mutations in melanoma (approx. 50% of all cases), the use of BRAF inhibitors in these 
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cases has been shown to improve the outcome in patients with melanomas harboring this mutation 
[291].  
 
While these novel therapeutic strategies have proven to significantly improve the OS and the general 
prognosis of patients with advanced melanoma, a considerable proportion of patients does not show a 
durable response to therapy and most of the compounds bring additional side effects like toxicity [292].  
 
Nevertheless, of new combinations of immunotherapeutic agents and targeted therapies are currently 
under development and tested in numerous clinical trials worldwide. Alongside with the discovery of 
new check-point inhibitors, the exploration of new targeted therapies for a more effective individual 
treatment will likely increase the effectivity of the current treatment strategies [290].  
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2.8. CCR6/CCL20 axis in melanoma 
The role of the CCR6/CCL20 axis in melanoma is still not completely understood and a matter of debate. 
The fact that this chemokine/CKR pair may control both the effectors (i.e. CCR6+ CD4+ T-cells, Th17 cells) 
and the regulators (i.e. immature CCR6+ DCs, CCR6+ T-regs) of an anti-melanoma immune response has 
contributed to this controversy [Fehler! Textmarke nicht definiert.]. Therefore targeting this axis in 
melanoma requires careful consideration and precise experimentation, and could only be of use under 
specific circumstances [Fehler! Textmarke nicht definiert.]. In fact, in order to obtain an effective 
therapeutic effect, inhibition of additional trafficking receptors could be necessary. For instance, it has 
been observed that the CCR1/CCL9 axis is capable of compensating the absence of CCR6/CCL20 in a 
series of conditions, such as the recruitment of DCs to Peyer’s Patches [140]. 
 
2.8.1. CCR6+ Immune subsets in melanoma 
A few studies have focused on the role of CCR6+ immune cells within melanoma tumors, mainly on DCs. 
It has been reported that melanoma patients show increased numbers of plasmacytoid DCs (PDCs) and 
myeloid DCs (MDCs) in the circulation. In this study, it was observed that PDCs expressed high levels of 
CCR6 and could migrate towards CCL20 expressing melanoma tumors, leading to an enhanced anti-
tumor immune response [293]. Other CCR6+ immune cell subsets have anti-tumor properties as well. For 
instance, Th17-polarized CD4+ T-cells are able to mediate the eradication of advanced melanoma in mice 
[294].  
 
However, other CCR6 expressing leucocytes may contribute to the generation a pro-tumorigenic 
environment. Accumulation of highly immunosuppressive leucocytes such as T-regs and memory T-cells 
in the tumor microenvironment contributes to tumor progression and enhanced metastasis in the Ret 
mouse model for melanoma [295].  In humans, CCR6+ is a marker for a subset of effector-memory T-cells 
that can hamper strong immune responses [296]. Nevertheless, the contribution of immunosuppressive 
CCR6+ leucocytes to melanoma tumor progression requires further research.  
 
2.8.2. CCL20 in the melanoma microenvironment 
It has been reported that some melanoma cells are able to produce and secrete CCL20 in the tumor 
microenvironment [297] and that the expression of this chemokine is highly upregulated in 3D cultures 
when compared with monolayer growing in vitro models [298]. Additionally, other cells within the 
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stroma such as tumor infiltrating macrophages can express CCL20. It has been shown that macrophage 
produced CCL20 can enhance the metastatic potential of melanoma tumors [141]. 
 
However the precise role of tumor CCL20 in melanoma progression has not been yet completely 
elucidated. A recent study using CCL20 DNA-vaccines in a B16 model for melanoma found that anti-
tumor immune response was enhanced when CCL20 was tagged with the melanoma antigen gp100. 
Coupling of CCL20 to Gp100 facilitated the activation of APCs like CCR6+ dendritic cells that later could 
activate effector T-cells faster than CCL20 alone [299]. 
 
2.8.3.   CCR6/CCL20 axis in melanoma progression 
In addition to CCL20, melanoma cells are also able to express CCR6 [141]. Recently a series of research 
groups have focused their efforts in unraveling the contribution of the CCR6/CCL20 axis to melanoma 
progression with ambiguous outcomes. Comparing intradermal melanoma tumor growth between Wt 
and CCR6-/- mice, no differences were found in terms of tumor growth or immune cell interactions. In 
this same study, researchers found no differences in the relative amounts of T-regs, Th17 and CD8+ 
effector T-cells within the tumor tissue and the regional lymph nodes of B16-F10 injected Wt  and CCR6-/- 
mice [300].  
 
On the other hand, loss of CCR6 in T-cells was observed to correlate with secondary lymphoid organ 
metastases. A decrease of CCR6 expression was also associated with increased lung metastases and a 
drop in CCR6+ T-cells has been highlighted as a hallmark of metastatic dissemination into the lymph 
nodes [301]. 
 
Thus, decrypting the contribution of CCR6 and CCL20 to melanoma growth and progression requires a 
comprehensive insight into the role of the different CCR6+ immune cell subsets, the specific contribution 
of the various CCL20 expressing cells and the effect of CCL20/CCR6 expression by melanoma cells. 
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3. AIM OF THE THESIS 
The general objective of this thesis was to evaluate the distinct functional contribution of CCR6 
interactions with CCL20 in modulating anti-melanoma immune response as well as to study the 
contribution of this chemokine axis to melanoma tumor growth and progression.  
 
To do so, we studied the kinetics and distribution of CCR6-guided immune cell subsets to the tumor site 
and draining lymph nodes (TDLN), as well as the effect of CCL20 on tumor initiation and progression in a 
CCR6 deficient environment. Furthermore, stimuli by which the expression of CCR6 ligands may be 
modulated at tumor site and/or the skin-draining LN and their potential relevance for anti-tumoral 
immune responses were part of our study.  
 
3.1. Aims and experimental approach 
1) In vitro  characterization of CCL20 expression by human and murine melanoma cell lines under   
homeostatic conditions and in response to inflammatory stimuli 
2) In vivo characterization of CCR6/CCL20 dependent immune responses in a transplantable B16 
melanoma model using Wild-type (Wt, C57BL/6J) and congenic CCR6 knock-out (CCR6-/-) mice by 
the analysis of  
a. Tumor growth kinetics  
b. Tumor microenvironment (TME) 
i) Cellular components: Tumor infiltrating Leucocytes (TILs) 
ii) Soluble components: cytokine/chemokine composition 
3) Study of potential autocrine effects of CCR6/CCL20 interactions in melanoma 
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4. MATERIALS & METHODS 
4.1. Buffers and Solutions 
 
Complete Medium: Dubebcos Modified Eagle Medium without L-Glutamine (DMEM, Gibco) with  
 10% Fetal Bovine Serum (FBS, Sigma-Aldrich) 
 1% 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, Sigma-Aldrich) 
 1% Penicillin/Streptomycin (Sigma-Aldrich)  
 1% L-Glutamine (Sigma-Aldrich) 
 1% MEM non-essential amino-acids (Ge-Healthcare) 
 
Digest Solution: Hank’s Balanced Salt Solution (HBSS, Biochrom-MERCK) with 1 μg/ml Collagenase IV 
(Sigma Aldrich) and 25 μg/ml DNAse I (Sigma Aldrich) 
 
Erythrocyte Lysis Buffer: Ammonium-Chloride-Potassium (ACK) lysis buffer pH 7.3. dH2O with: 
 155 mM NaH4Cl 
 10 mM KHCO3 
 130 mM EDTA (Disodium ethylenediaminetetraacetate dehydrate) 
 
FACS Buffer (for FCM): 3% FBS in PBS  
 
Freezing Medium 
 50% Complete Medium 
 30% FBS (Sigma-Aldrich) 
 20% Dimethyl sulfoxide (DMSO, Sigma-Aldrich) 
 
Percoll gradient solutions: Percoll™ (GE-Healthcare) 
 40%: 60% DMEM (with 1% L-Glutamine), 36% Percoll, 4% 10X PBS 
 80%: 20% DMEM (with 1% L-Glutamine), 72% Percoll, 8% 10X PBS 
Phosphate Buffered Saline (PBS): 1% PBS Dulbecco powder (Biochrom-MERCK) in dH2O pH 7.4  
 
Wash Buffer (for FCM): HBSS with 0,1% Bovine Serum Albumin (BSA, Sigma-Aldrich)  
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4.2. Cell lines and cell culture 
Murine Ret and Human C32 and A375 melanoma cells were gently provided by Daniel Roth from the 
German Center for Cancer Research (DKFZ) in Heidelberg, Germany. Murine B16/F1 melanoma cells 
(referred to as B16) transduced with cDNA encoding firefly (Photinus puralis) luciferase (B16-luc) in the 
PMSCV retroviral vector (Clontech) [302], were the kind gift from Dr. Sam Hwang (Medical College of 
Wisconsin) 
 
Human (C32, A375) and murine (B16, Ret) melanoma cells were cultivated in Complete Medium, and 
incubated at 37 º C in a 5% CO2 environment. 4x105 cells were cultured in T75 flasks and passed after 
detection of 70-80% of visual confluence twice a week, washing them previously with room temperature 
(RT) PBS and detaching with trypsin (GE Healthcare). 10μg/ml puromycin (Pur) was added for PMSCV-
vector (Luciferase) selection to culture medium of B16 melanoma cells after each passage. 
 
4.3. CCL20 detection by Enzyme-Linked Immunoabsorbent Assay (ELISA) 
5x104 human (C32, A375) and murine (B16, Ret) melanoma cells were seeded in 24-well plates (Falcon) 
and stimulated with increasing concentrations of human or murine TNF-α (50, 100 and 200 ng/ml) and 
human or murine IL-1α (10, 20 and 40 ng/ml) alone or combined (50ng/ml TNF-α + 10 ng/ml IL-1α) for 
24, 48 and 72h. After these time-points supernatants were collected and centrifuged to eliminate cells in 
suspension. CCL20 was then measured by means of ELISA following the guidelines from human and 
murine CCL20 detection kits (R&D Systems) and analyzed with a Multiskan Ex ELISA plate reader 
(Thermo-Fischer). All incubation times were performed at 37 º C in a 5% CO2 environment. 
 
4.4. Generation of retrovirally transduced melanoma cells  
B16-luc-PMSCV cells were cultured for up to 15 passages until stimulation with TNF-α was not capable to 
induce CCL20 expression anymore. This CCL20-non-expressing cell line (B16 parental), alongside with 
two pLNCX2 vectors (one carrying a mCCL20 gene) from (Clontech) were provided to Dr. Rainer Will from 
the Stable Isogenic Cell line Service at the German Center for Cancer Research (DKFZ, Heidelberg) in 
order to generate two retrovirally transduced B16 cell lines. Using “Sir” cell line technology Dr. Will 
provided us with two new cell lines, B16-Control (B16 cells transduced with the empty pLNCX2 vector) 
and B16-CCL20 (B16 cells transduced with the CCL20 bearing pLNCX2 vector). Both pLNCX2 vectors 
carried a selection gene resistant to G418-sulphate. Therefore in addition to 10μg/ml Pur, 400μg/ml of 
G418-sulphate was added to the medium of B16-Control and B16-CCL20 cells after each passage. 
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To measure CCL20 homeostatic expression, 5x104 cells of each newly generated cell line were seeded 
into 24-well plates and supernatants were collected and analyzed by means of ELISA after 24, 48 or 72 h. 
 
In order to confirm in vivo CCL20 expression, 4x105 cells of B16-Control and B16-CCL20 cell lines were 
injected subcutaneously in the right flank of Wt and CCR6-/- that had been shaved locally 24 hours 
before. 15 days after inoculation, animals were sacrificed, tumors were dissected and blood samples 
were taken.  
 
Tumor digestion was performed by manual fragmentation followed by 1,5 hours of incubation with 
Digest Solution at 37ºC and filtered through a 70 μm strainer (Falcon). The resulting suspension was 
centrifuged at 200g and CCL20 was analyzed from the remaining supernatant by means of ELISA in 96-
well plates (Falcon). Blood was extracted by cardiac puncture, centrifuged at 7000 g and CCL20 was 
measured from the serum by means of ELISA in 96-well plates (Falcon) 
 
4.5.  XTT proliferation assay 
5x104 B16-Control and B16-CCL20 cells were seeded in 96-well plates (Falcon) and cultured for 24 and 
48h with different concentrations of mCCL20 (PeproTech) as indicated. XTT/PMS solution was prepared 
according to the XTT kit protocol of the manufacturer (Advance Targeting Systems). 50 ul of XTT/PMS 
were added to each well and plates were incubated for 2h at 37ºC. Absorbance was measured at 450 nm 
with a Multiskan Ex ELISA plate reader (Thermo-Fischer). 
 
4.6. Wound Healing Assay 
1x105 B16-Control and B16-CCL20 cells were seeded in 12-well plates (Falcon) and cultured at 37 º C in a 
5% CO2 environment to near confluence. After 6h of culture with complete medium without FBS, a linear 
wound was created gently by scraping a 100 ul sterile pipette tip through the complete diameter of the 
cell monolayer. Subsequently the well was washed twice with PBS to remove detached cells. The 
monolayers were further incubated at 37 º C in a 5% CO2 environment with complete medium without 
FBS and photographs (x20 magnification) of the wounds were taken at 0, 4, 8 and 24h after wounding. 
Percentage of wound-closure was calculated using ImageJ Software.  
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4.7. Flow-cytometry (FCM) of melanoma cells 
5x105 B16-Control and B16-CCL20 melanoma cells were seeded in 24-well plates (Falcon) with complete 
medium. After 24h cells were washed with RT PBS and detached with trypsin (GE Healtcare). Cells were 
suspended in FACS buffer and incubated at 4 º C with anti-mouse CD16/32 (eBioscience, Cl 93) at a 1:100 
concentration for 10 mins in order to block the Fc receptors. Cells were then washed and incubated for 
30 min with APC-labeled anti-CCR6 (Biolegend, Cl 29-2L17) and APC-labeled Armenian Hamster IgG 
Isotype Ctrl Antibody (Biolegend, HTK888) at 37ºC to enhance CKR turnover. Cells were then washed and 
7AAD (eBiosciences) was added as a death cell marker before measuring CCR6 signal by means of FCM. 
All samples were analyzed using a Galios 10 Colors, 3 Lasers (B15-R1-V2 Configuration) flow cytometer 
from Beckman Coulter.  
 
 
4.8. Mice strains and stabling 
Wild-type (Wt) C57BL/6J mice were purchased from Charles River Laboratories (Germany). Congenic 
C57BL/CCR6-/- (CCR6-/-) mice, generated as previously described [162], were kindly provided by Joshua M. 
Farber (Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases 
(NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA) and redeliver by embryonic 
transfer at the Interfacultary Biomedical Faculty (IBF) of Heidelberg University (Heidelberg, Germany). All 
mice were maintained in specific pathogen-free conditions at the IBF of Heidelberg University and used 
for experiments at 6-8 weeks of age. Animal care and procedures followed the regulations, specifications 
and obligations given by the German protection of Animals Act. All experimental procedures were 
approved by the institutional review boards and performed in accordance with the institutional 
guidelines for animal welfare.  
 
4.9. Tumor growth experiments 
The right flank of Wt and CCR6-/- mice was shaved 24 hours before tumor cell inoculation. 4x105 B16, 
B16-Control or B16-CCL20 melanoma cells were subcutaneously injected in the right flank. Tumor growth 
was monitored every day after tumor inoculation using a caliper. Tumor area (TA) was calculated with 
the formula: TA = (major radius)*(minor radius)*π. Mice were routinely euthanized using CO2 15 days 
after tumor inoculation followed by dissection and tumor and lymph node extraction. In accordance with 
the institutional guidelines for animal welfare, mice were euthanized earlier in case that the diameter of 
the tumor reached >20 mm or the animal showed signs of suffering or discomfort. 
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For the evaluation of the effect of recombinant mCCL20 (rCCL20) on B16-Control tumor progression, 
local injections of rCCL20 (PreproTech) were administrated every 2 days at the site of tumor injection 
from day 2 after inoculation. The amount of injected rCCL20 was modulated according to tumor size: 50 
ng for tumors up to 75 mm2, 100 ng for tumors between 75-125 mm2 and 200ng for tumors bigger than 
125 mm2. 
 
For the evaluation of the effect of anti-mCCL20 (aCCL20) antibodies on B16-CCL20 tumor progression, 
local injections of aCCL20 (Biotechne, Cl 114908) were administrated every 2 days at the site of tumor 
injection from day 2 after inoculation. The amount of injected aCCL20 was modulated according to 
tumor size: 100 ng for tumors up to 75 mm2, 200 ng for tumors between 75-125 mm2 and 400ng for 
tumors bigger than 125 mm2 
 
4.10. Cell isolation 
For the isolation of TILs, tumors were dissected and DLN were separated before digestion. Digestion was 
performed by manual fragmentation followed by 1,5 hours of incubation with Digest Solution at 37ºC. 
The resulting suspension was centrifuged at 50g to remove undigested skin remnants, and the collected 
supernatant was then centrifuged at 200g. After this centrifugation the supernatant was collected for a 
posterior analysis by Legendplex (see 4.12) and the pellet was washed twice with Wash Buffer and 
centrifuged again at 200 g. Pellets were then incubated for 3 minutes with Erythrocyte Lysis Buffer at RT. 
After another washing step, pellets were resuspended in 40% Percoll solution and gently placed in falcon 
tubes containing 80% Percoll solution. Falcon tubes were centrifuged at 325g for 23 min at RT, with low 
ascending and descending rates. Interface between 40% and 80% Percoll layers was collected and 
filtered through a 40μm cell strainer. Filtrated suspension was washed and centrifuged at 425g for 10 
min at RT. The resulting cell pellet was resuspended in 100 μl FACS buffer and analyzed by means of 
FCM.  
 
For the isolation of DLN immune cells, lymph nodes were manually disrupted over a 40μm cell strainer 
(Falcon) and the collected suspension was washed twice with FACS buffer before proceeding to FCM 
analysis.  
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4.11. Flow cytometry of TILS and DLN immune cells  
Each sample of isolated TILs and DLN cell suspensions was split in half to be analyzed with two different 
panels of antibodies: Panel A and Panel B. All samples were analyzed using a Galios 10 Colors, 3 Lasers 
(B15-R1-V2 Configuration) flow cytometer from Beckman Coulter. For the Panel A, cells were suspended 
in FACS buffer and incubated with anti-mouse CD16/32 (eBioscience, Cl 93) for 10 mins in order to block 
the Fc receptors. Cells were then washed and incubated at 4 º C for 30 mins with Panel A antibody 
combination. After an additional washing step, 7AAD was added and cells were analyzed by means of 
FCM. All incubations were performed at 4ºC and all washing steps were done with cold FACS buffer.    
Panel A antibody combination 
Antigen Fluorophore Clone Company Working Concentration 
CD45R FITC RA3-6B2 eBioscience 1:200 
CD8 PE 53-6.7 BD Pharmigen 1:200 
CCR6 APC 29-2L17 Biolegend 1:100 
CD5 APC-alexa780 53-7.3 eBioscience 1:200 
CD3 Pacific Blue 145-2C11 Biolegend 1:200 
CD19 BlueViolet510 103 BD Pharmigen 1:200 
Dead Cell Marker 7AAD - Invitrogen 1:100 
 
For Panel B cells were suspended in FACS buffer and incubated with Zombie Violet at RT for 10 minutes. 
After a washing step, Fc block and Panel B antibody combination staining was performed as described 
for panel A, without adding PE anti-FoxP3. After antibody staining, cells were resuspended in fixation 
buffer from the FoxP3 fixation/staining kit from (Invitrogen) and FoxP3 staining was performed according 
to the guidelines from this kit. Once this was performed, fixed cells were resuspended in FoxP3 
fixation/staining kit wash buffer and analyzed by means of FCM. 
Panel B antibody combination 
Antigen Fluorophore Clone Company Working Concentration 
CD45R FITC RA3-6B2 eBioscience 1:200 
Foxp3 PE FJK-165 Invitrogen 1:100 
CCR6 APC 29-2L17 Biolegend 1:100 
CD11c APC-alexa780 N418 eBiosciences 1:200 
CD3 Pacific Blue 145-2C11 Biolegend 1:200 
CD4 BlueViolet510 RM4-5 Biolegend 1:200 
Dead Cell Marker Zombie Violet - Biolegend 1:1000 
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4.12. LEGENDPLEX 
Cytokine composition from cultured melanoma cells and fresh supernatants from dissected tumors were 
analyzed by means of LEGENPLEX™ technology (BioLEGEND). Samples were incubated with antibody-
tagged beads in 96-well plates and analyzed by means of FCM following the guidelines from the product 
protocol. Data was analyzed by using the LEGENDPLEX™ Software (v7.1). A customized bead combination 
was designed to detect the concentration of IL-1α, IL-6, IL-9, IL-10, IL-12p70, IL-17A, IL-22, IL-23, IL-27, 
INF-ɣ, TNF-α, TSLP and CCL2.  
 
4.13. STATISTICAL ANALYSIS 
In vitro results are represented as the mean ± standard deviation (SD) of the indicated number of 
independent experiments and significance was calculated using Two-tailed Student T-test. In vivo results 
are represented as the mean ± standard error of the mean (SEM) of the indicated number of 
independent experiments and significance was calculated using Two way ANOVA, Bonferroni post-test. 
All statistical calculations were performed with GraphPad Prism software. P-value < 0.05 was considered 
as statistically significant.  
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5. RESULTS 
5.1. CHARACTERIZATION OF CCL20 EXPRESSION BY MELANOMA CELLS 
5.1.1. mCCL20 expression by murine melanoma cells in vitro .  
In order to test the capability of murine melanoma cell lines to produce CCL20, we cultured B16 and Ret 
mouse melanoma cells for 24, 48 and 72h in complete growth medium in presence or absence of pro-
inflammatory cytokines mTNF-α and mIL-1α, which have been described to upregulate CCL20 in certain 
cell types [297] and are present in the tumor microenvironment [303,304]. Cell culture supernatant was 
collected after each time point and mCCL20 levels were measured by means of ELISA.  
 
Under homeostatic conditions mCCL20 production was weak or non-existent. However, it could be 
triggered upon stimulation with pro-inflammatory cytokines. Stimulation with increasing concentrations 
of either mTNF-α or mIL-1α induced a significant increase of mCCL20 expression after 48h. In the case of 
stimulation with mTNF-α, significant increases of mCCL20 could be observed after 24h. Overall mTNFα 
was able to induce significantly higher levels of mCCL20 than mIL-1α (Fig. 1). 
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Figure 1. Murine melanoma cell lines express mCCL20 in vitro  under stimulation with mTNF-α and mIL-1α. 5x10
4
 
Ret1 and B16 melanoma cells were seeded in 24 well plates, stimulated with increasing concentrations of TNF-α or 
co-stimulated with mTNF-α and mIL-1α. Medium was removed after 24, 48 and 72 hours respectively and mCCL20 
was measured by means of ELISA. (h.p.s., hours post stimulation) A. Total mCCL20 detected in the supernatants 
expressed in pg/ml. B. pg of mCCL20 produced per 1000 melanoma cells. Bar graphs represent mean ±SD from 
three independent experiments. Unpaired T-test (* P<0.05, ** P<0.005, *** P<0.0005) 
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5.1.2. hCCL20 expression by human melanoma cells in vitro.  
We performed similar experiments described in the previous section using two human melanoma cell 
lines (C32 and A375) in order to verify hCCL20 production capability (Fig. 2). 
 
Our results paralleled with those obtained using murine melanoma cell lines. Both human melanoma cell 
lines showed weak or non-detectable hCCL20 expression under homeostatic conditions, but expression 
could be triggered after being cultured in presence of hTNF-α or hIL-1α. However, especially in the case 
of C32 melanoma cells, the magnitude of the responses to these pro-inflammatory cytokines were 
significantly weaker compared to B16 or Ret murine melanoma cell lines. Additionally, co-stimulation 
with hTNF-α and hIL-1α resulted in a tremendous increase on hCCL20 production after 72h in A375 cells, 
while in C32 cells, addition of hTNF-α and hIL-1α caused the same effect as hTNF-α alone.  
 
Altogether, these results showed that the constitutive expression of CCL20 in both murine and human 
melanoma is weak or non-detectable in vitro . However CCL20 expression can be easily triggered by pro-
inflammatory cytokines. Additionally, the magnitude of CCL20 induction upon stimulation varies 
between different melanoma cell lines.  
 
  
Results 
~ 61 ~ 
 
A 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
Figure 2. Human melanoma cell lines express hCCL20 in vitro under stimulation with hTNF-α and hIL-1α. 5x10
4
 
A375 and C32 human melanoma cells were seeded in 24 well plates and stimulated with increasing concentrations 
of hTNF-α or co-stimulated with hTNF-α and hIL-1α. Medium was removed after 24, 48 and 72 hours respectively 
and CCL20 was measured by means of ELISA (h.p.s., hours post stimulation). A. Total hCCL20 detected in the 
supernatants expressed in pg/ml. B. pg of hCCL20 produced per 1000 melanoma cells. Bar graphs represent mean 
±SD from three independent experiments. Unpaired T-test (* P<0.05, ** P<0.005, *** P<0.0005) 
 
5.1.3. CCL20 expression decreases over in vitro passages in B16 melanoma cells 
Our collaborator Prof. Fran Balkwill from Barts Cancer Institute in London communicated that she 
commonly observes a loss of chemokine expression after 10 or more passages in several cell lines 
cultured in vitro, and recommended to monitor carefully any loss of expression. Subsequent research of 
literature led to find similar phenomena in some publications [305,306]. Indeed CCL20 production 
progressively decreased after in vitro passages (Fig. 3). We observed that this “passage effect” was 
taking place in other melanoma cell lines as well.  
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Figure 3. mCCL20 expression capability in melanoma cells is lost after several passages in vitro . B16-PMSCV cells 
were kept in culture for several passages. In the figure, mCCL20 expression capability was tested over several 
passages. Figure shows representative data from early (Left, passage 8) and late (right, passage 25) in vitro 
passages. 5x10
4
 cells were seeded in 24 well plates and stimulated with increasing concentrations of mTNF-α or co-
stimulated with mTNF-α and mIL-1α. Medium was removed after 24, 48 and 72 hours respectively and mCCL20 
amounts were measured by means of ELISA. (h.p.s., hours post stimulation) Bar graphs represent mean ±SD from 
three independent experiments. Unpaired T-test (* P<0.05, ** P<0.005, *** P<0.0005) 
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5.2. B16 melanoma growth in C57BL/6J (Wild-type, Wt) and congenic CCR6 knock-
out (CCR6-/-) mice 
 
Two different mouse strains were used for the in vivo experiments: C57BL/6J “Wild-type” mice and 
congenic CCR6 knock-out mice (C57BL/6J Background), that we will refer to subsequently as Wt and 
CCR6-/- mice.   
 
5.2.1. CCL20 levels in serum of Wt and CCR6-/- mice 
We took serum samples from Wt and CCR6-/- animals and measured CCL20 levels by means of ELISA. 
Results showed that presence of CCL20 protein in the serum was minimal under homeostatic conditions 
and did not significantly differ between Wt and CCR6-/- mice (Fig. 4). 
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Figure 4. Wt and CCR6
-/-
 animals have low concentrations of mCCL20 in serum. Blood was taken from healthy Wt 
and CCR6
-/-
 animals and mCCL20 levels of the serum were measured by means of ELISA. Unpaired T-test.  
 
5.2.2. Effect of CCL20 expression levels on B16 tumor growth in Wt and CCR6-/- mice  
We inoculated 4x105 of early passaged (passage-8) B16 melanoma cells subcutaneously in the flank of 
Wt and CCR6-/- mice in order to monitor tumor growth over 15 days. mCCL20 expression capability of 
B16 melanoma cells was confirmed in vitro  during the first days after inoculation (Fig. 5A). In vivo, we 
observed significantly slower B16-tumor growth in CCR6-/- compared to Wt mice (Fig. 5B).  
 
However no differences could be observed in tumor growth between the two experimental groups when 
using late passaged (passage-20) B16 melanoma cells. Additionally, tumors from both Wt and CCR6-/- 
grew significantly faster than in the previous experiments. In vitro analysis of the mCCL20 expression 
capacity of the late passage (>20 passages) B16 melanoma cells revealed, that mCCL20 expression 
capability was nearly lost in these cells (Fig. 5C).   
Results 
~ 64 ~ 
 
Wt mice 
CCR6
-/-
 mice 
B16 melanoma cells 
mCCL20 ELISA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Tumor progression in Wt and CCR6
-/-
 mice injected with early (passage-8) and late (passage-20) passages of B16 
melanoma cells. 4x10
5
 B16 melanoma cells were injected s.c. in the flank of the mice. Tumor growth was measured daily using a 
caliper. Tumor area = (major radius)*(minor radius)*π.. A. Illustrative scheme of the experimental setup  B. mCCL20 production 
capability of inoculated B16-cells the day of the experiment after 8 passages in culture (Left) and progression of tumor growth 
over time (Right). C. mCCL20 production capability of inoculated B16-cells the day of the experiment after 20 passages in culture 
(Left) and progression of tumor growth over time (Right). Bar graphs represent mean ±SD from three independent experiments. 
Unpaired T-test (* P<0.05, ** P<0.005, *** P<0.0005). Dots represent means ±SEM of 5 mice in each group. Two-way ANOVA, 
Bonferroni post-test.  (h.p.s., hours post stimulation; p.i., post inoculation) 
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5.3. Generation of retrovirally transduced mCCL20 expressing B16 melanoma cells  
 
5.3.1. Aim and introduction 
Due to the detected variations in mCCL20 expression during in vitro  culture and the substantially effect 
in vivo tumor growth, accurate positive and negative controls were required for future animal 
experiments. On one hand a cell line capable of robust mCCL20 expression under homeostatic conditions 
and on the other hand one that had lost CCL20 expression capability completely.  
 
With that aim, we cultured B16 cells in our lab for 15 passages until stimulation with mTNF-α could not 
trigger mCCL20 expression anymore. We obtained Retroviral transduction of B16 melanoma cells was 
carried out in the German Center for Cancer Research (DKFZ) in collaboration with Prof. Rainer Will, 
using pLNCX2 plasmid vectors from Clontech, one of which carried the murine gene for CCL20 (pLNCX2-
CCL20). (Scheme 1) 
 
Scheme 1. B16-Control and B16-CCL20 cell lines were generated from a parental B16 cell line. 
 
5.3.2. mCCL20 expression in retrovirally transduced B16 clones 
Once B16 cells were retrovirally transduced with control pLNCX2 or pLNCX2-CCL20 vectors, mCCL20 
expression capability under homeostatic conditions was tested for six different clones from each new 
cell line by means of ELISA. 
 
None of the pLNCX2-control B16 melanoma cells expressed CCL20 under homeostatic conditions (Fig 6A, 
right) while two out of six pLNCX2-CCL20 B16 clones expressed CCL20 under homeostatic conditions (Fig 
6A, left).  
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5.3.3. Selection of clones for in vivo experiments 
Out of the positively transduced pLNXC2-CCL20 clones, the clone that showed higher mCCL20 expression 
levels under homeostatic conditions was selected for future in vivo experiments. In order to select an 
appropriate control counterpart for these cells, proliferation capability of all pLNCX2-control clones was 
tested by means of XTT assay and compared to the CCL20 expressing B16 cell line, choosing the clone 
that showed the closest similarity (Fig. 6B). These cell lines were renamed as B16-CCL20 and B16-Control 
and used for the subsequent in vitro and in vivo experiments of this project. Stimulation with mTNF-α 
could not trigger significant mCCL20 expression in B16-Control cell lines and did not increase significantly 
mCCL20 production in B16-CCL20 cells (Fig 7) as measured by ELISA. Additionally, we tested whether, 
besides mCCL20 expression, the retroviral infection procedure had affected the expression of other pro-
inflammatory cytokines by means of LEGENDPLEX assay. Both B16-Control and B16-CCL20 responded in 
a similar manner, as well as the parental B16 melanoma cell line (Fig 8).  
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Figure 6. Selection of retrovirally transduced B16-CCL20 and B16-Control melanoma cells for future in vivo 
experiments. Retroviral transduction was carried out at the Genomics & Proteomics core Facility from the German 
Center for Cancer Research (DKFZ) under supervision from Prof. Rainer Will. pLNCX2-CCL20 clone 1 and pLNCX2-
CCL20 clone 3 were picked up and renamed as B16-CCL20 and B16-Control A. All clones were cultured following the 
A 
B 
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same protocol in 3.1 and mCCL20 was detected by means of ELISA (h.p.s., hours post seeding). Bar graphs show 
mean ±SD from three independent experiments. B. Results from XTT proliferation assay from B16-CCL20 and B16-
Control cells. Bar graphs show mean ±SD from two independent experiments. Unpaired T-test (* P<0.05,** 
P<0.005,*** P<0.0005).         
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Figure 7. Stimulation with TNF- α cannot trigger significant mCCL20 expression in B16-Control cell lines. 5x104 
B16-CCL20 and B16-Control melanoma cells were seeded in 24 well plates and stimulated with increasing 
concentrations of TNF-α. Medium was removed after 24, 48 and 72 hours respectively and CCL20 was measured by 
means of ELISA. Bar graphs represent mean ±SD from three independent experiments. Unpaired T-test (* P<0.05) 
 
 
 
 
 
 
 
Figure 8. TNF-α triggers similar cytokine responses in retrovirally generated B16 melanoma cells. 5x10
4
 B16-
CCL20, B16-Control and B16 parental cells were seeded in 24 well plates and stimulated with increasing 
concentrations of TNF-α. Medium was removed after 48 hours respectively and concentrations of 13 different 
inflammatory cytokines were measured by means of LEGENDPLEX.  
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5.3.4. In vivo expression of mCCL20 by retrovirally transduced B16-PMSCV clones 
Complementing our in vitro  analysis, we tested the mCCL20 expression capability of B16-CCL20 and B16-
Control in vivo. CCL20 could be detected in the supernatants from tumors of Wt and CCR6-/- mice 
subcutaneously injected with B16-CCL20 melanoma cells. By contrast, mCCL20 was barely detectable in 
supernatants from B16-Control tumors in Wt and CCR6-/- animals (Fig. 9). mCCL20 could also be detected 
in the serum from Wt and CCR6-/- mice subcutaneously injected with B16-CCL20, but not in those 
injected with B16-Control cells. (Fig 10)  
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Figure 9. mCCL20 expression of retrovirally transduced melanoma cells in vivo. 4x10
5
 cells from B16-Control or 
B16-CCL20 cells were subcutaneously injected at the flank of Wt and CCR6
-/-
 mice. Tumors were removed and 
digested after 15 days. mCCL20 was measured from the supernatants by means of ELISA. Unpaired T-test (*** 
P<0.0005) 
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Figure 10. mCCL20 can be detected in serum from B16-CCL20 injected mice. Blood was taken from B16-Control 
and B16-CCL20 subcutaneously injected Wt and CCR6
-/-
 animals 15 days after inoculation. mCCL20 in serum was 
measured by means of ELISA. Unpaired T-test (** P<0.005, *** P<0.0005) 
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5.3.5. Loss of mCCL20 expression in retrovirally transduced cell lines affects tumor growth in 
CCR6-/- mice 
The experiment described in 3.2.3 was repeated by inoculating both cell lines in Wt and CCR6-/- animals 
in order to observe if overexpression of mCCL20 at the tumor site would create differences in tumor 
progression. Wt and CCR6-/- mice were divided into two groups each and subcutaneously injected either 
with B16-Control or B16-CCL20 melanoma cells (Scheme 2) 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2. Illustrative scheme showing established experimental groups. 10 Wt and 10 CCR6
-/-
 mice were divided 
in two groups each and injected with B16-Control and B16-CCL20 melanoma cells respectively on each experiment. 
 
In this first experiment no differences in tumor progression were observed between the B16-Control 
injected Wt and CCR6-/- groups. However, in the B16-CCL20 experimental groups, while Wt animals 
showed similar tumor growth rate than B16-Control injected groups, CCR6-/- mice developed tumors 
significantly slower (Fig. 11A). Similar to our previous observations using B16 parental cells, Wt and 
CCR6-/- animals injected with B16-CCL20 cells showed no significant differences when using late passaged 
cells (>15 passages) (Fig. 11B) corresponding with a significant reduction of CCL20 expression capability 
as measured under homeostatic conditions in vitro  (Fig. 11C).  
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Figure 11. Reduction of mCCL20 homeostatic expression in B16-CCL20 cells affects tumor growth in CCR6
-/-
 mice. 
4x10
5
 cells of B16-Control or B16-CCL20 were injected s.c. in the flank of Wt and CCR6
-/-
 mice. Tumor growth was 
measured daily using a caliper. Tumor area = (major radius)*(minor radius)*π. Dots represent means ±SEM of 5 
mice in each group. Two-way ANOVA, Bonferroni post-test.  A. Tumor growth from early passaged B16-Control and 
B16-CCL20 injected mice B. Tumor growth from late passaged B16-Control and B16-CCL20 injected mice C. CCL20 
expression under homeostatic conditions from early passaged (pass. 4) B16-Control and B16-CCL20 cells D. CCL20 
expression under homeostatic conditions from late passage (pass. 15) B16-Control and B16-CCL20 cells. Bar graphs 
represent mean ±SD. Unpaired T-test (* P<0.05, ** P<0.005, *** P<0.0005)   
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5.4. CCR6-/- mice develop significantly slower melanoma tumors in presence of 
CCL20 
5.4.1. Aim and introduction 
In order to study the effect of mCCL20 overexpression during melanoma progression in Wt and CCR6-/- 
animals regarding tumor growth kinetics, survival rate and onset, experiments described in 3.3.6 were 
repeated using early passaged (pass 2-6) B16-Control and B16-CCL20 cells each time 
 
5.4.2. Wt and CCR6-/- mice injected with B16-CCL20 melanoma cells show significantly smaller 
tumors compared to controls and Wt mice. 
Again, four experimental groups as described in Scheme 2 were established. Cells were inoculated 
subcutaneously in the flank of mice that had been shaved locally 24h before the experiment. Tumor size 
was monitored daily for a period of 15 days by using a caliper. Animals that did not develop tumors by 
this time point were kept under surveillance 3 extra days before being sacrificed in order to verify that 
no late-onset tumors would develop. 
 
On day 15, animals injected with B16-CCL20 cells had smaller tumors than their B16-Control injected 
littermates. These differences were significantly higher in   CCR6-/- mice. 
 
In both experimental groups CCR6-/- animals displayed smaller tumors than Wt animals. In the case of 
B16-Control injected groups, CCR6-/- mice showed slightly significant differences compared to their Wt 
analogues. However B16-CCL20 injected CCR6-/- animals showed significantly smaller tumors than the 
B16-CCL20 injected Wt group (Fig 12A and 12B). 
  
Results 
~ 72 ~ 
 
 
                  
 
 
 
 
 
 
0
25
50
75
100
125
150
175
4 6 8 10 12 14 16
CCR6-/- (B16-Control)
Wt (B16-CCL20)
CCR6-/- (B16-CCL20)
Wt (B16-Control)
**
*
*
Melanoma tumor growth
Days p.i.
T
u
m
o
r 
a
re
a
 (
m
m
2
)
 
0
20
21
22
23
24
25
26
27
28
4 6 8 10 12 14 16
CCR6-/- (B16-Control)
Wt (B16-CCL20)
CCR6-/- (B16-CCL20)
Wt (B16-Control)
**
*
*
Melanoma growth gradient
Days p.i.
L
o
g
 t
u
m
o
r 
a
re
a
 (
m
m
2
)
 
Figure 12. B16-CCL20 injected mice show slower melanoma tumor growth than B16-Control injected controls. 4x10
5
 cells of 
B16-Control or B16-CCL20 were injected s.c. in the flank of Wt and CCR6
-/-
 mice. Tumor growth was measured daily using a 
caliper. A. Illustrative pictures of melanoma tumors from Wt and CCR6
-/-
 mice injected either with B16-CCL20 or B16-Control 
cells at day 12 after tumor inoculation. B. Tumor growth kinetics from all four experimental groups. Tumor area = (major 
radius)*(minor radius)*π. Dots represent means ±SEM of 25 mice in each experimental groups form 5 independent 
experiments. Two-way ANOVA, Bonferroni post-test (** P<0.005,*** P<0.0005). C. Tumor growth data from B transformed into 
log2 scale. 
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5.5. B16-CCL20 injected CCR6-/- mice showed differences in tumor growth rate, 
visual onset and incidence compared to controls and Wt mice 
5.5.1. B16-CCL20 tumors in CCR6-/- mice maintain a constant tumor growth rate over time 
In a recent publication Gegenbacher and collaborators highlighted the limitations of classical tumor data 
representation and suggested to display tumor size kinetics using logarithmic scales [307] Displaying 
tumor growth data by logarithmic scale we noted that tumors from B16-CCL20 injected CCR6-/- mice 
doubled their size every 48 hours once they became visible, kept this gradient over time and showed a 
delayed onset compared to the rest of the experimental groups. This phenomenon contrasts with the 
growth gradient of tumors from both Wt experimental groups and B16-Control inoculated CCR6-/- 
animals. In all these three experimental groups, tumors doubled their size every 24 hours during the first 
days after becoming visible, and every 48 hours from day 8 on. Based on this we divided tumor growth 
kinetics from Wt and B16-Control injected CCR6-/- animals into two different stages: One initial stage 
characterized by high growing gradient followed by a second stage of stable constant tumor growth (Fig 
12C). Interestingly, while CCR6-/- experimental groups showed differences in tumor growth gradients and 
final tumor size, Wt experimental groups showed similar tumor growth gradients despite of the 
differences in final tumor size. 
 
5.5.2. B16-CCL20 tumors from CCR6-/- mice showed later visual onset 
Tumors arising in B16-Control and B16-CCL20 injected Wt animals were spotted visually (>2 mm Ø) at 
days 5-6, as well as tumors from B16-Control injected CCR6-/- mice. By day 9 after inoculation 80% of the 
animals on these three experimental groups had developed tumors. On the contrary, while first tumors 
from B16-CCL20 injected CCR6-/- animals could be detected between days 6-7, by day 9 the proportion of 
mice with visible tumors was only 20% (Fig 12C and 13A). Overall, visual onset of tumors arising in B16-
CCL20 injected CCR6-/- mice was significantly delayed compared to both Wt experimental groups and 
B16-Control injected CCR6-/- group. 
 
5.5.3. B16-CCL20 injected CCR6-/- mice have lower tumor incidence 
In terms of tumor incidence almost 100% of B16-Control and B16-CCL20 injected Wt individuals had 
developed tumors by the end of the experiment (up to day 18). In the case of CCR6-/- mice, all of those 
injected with B16-Control cells developed tumors before day 18 after tumor inoculation. However, only 
76% of the specimens from the B16-CCL20 injected CCR6-/- group had developed tumors by this time 
Results 
~ 74 ~ 
 
point. Hence, almost 25% of the animals from this experimental group did not develop melanoma 
tumors at the inoculation site during the time of the experiment (Fig. 13A and 13B) 
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Figure 13. B16-CCL20 injected CCR6
-/-
 mice show later melanoma onset and reduced tumor incidence. A. 
Percentage  of individuals with visible tumors (>2 mm diameter) over time. Log-rank (Mantel-Cox) test                  
(*** P<0.0005) B. % of animals that had developed tumors by day 18 after inoculation. In Both cases figures 
represent data from 25 mice on each experimental group taken from 5 independent experiments. 
 
5.5.4. Local injections of rCCL20 decrease tumor growth in B16-Control inoculated CCR6-/- 
mice 
Our previous experiments indicated that the constant presence of B16-derived CCL20 at the site of a 
growing tumor influenced tumor size and growing gradient. In order to test that these differences in 
growth were indeed caused by CCL20, we established a similar experimental model injecting B16-Control 
cells in Wt and CCR6-/- mice followed by local injections of recombinant murine CCL20 (rCCL20) every two 
days into the site of the tumor, increasing the injected amounts of rCCL20 proportionally as tumors were 
growing (Fig 14A). 
 
In line with previous experiments no significant differences in tumor growth between CCL20 and PBS 
injected Wt mice were observed. However, rCCL20 injected CCR6-/- animals developed tumors 
significantly slower than their PBS injected littermates. The PBS injected CCR6-/- group showed no 
significant differences in tumor growth compared to both Wt groups (Fig 14B).  
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Figure 14. B16-Control tumors from inoculated CCR6
-/-
 mice develop slower after local injections of rCCL20 when 
compared to controls. 4x10
5
 cells of B16-Control cells were injected s.c. in the flank of Wt and CCR6
-/-
 mice. Local 
injections of recombinant CCL20 or PBS were provided every two days after tumor inoculation. Tumor growth was 
measured daily using a caliper. A. Illustrative scheme of the experimental set up. Two additional groups of Wt and 
CCR6
-/-
 mice were provided periodical injections of PBS after B16-Control melanoma cell inoculation as a control. B. 
Melanoma tumor growth from all four experimental groups. Tumor area = (major radius)*(minor radius)*π. Dots 
represent means ±SEM of 10 mice on each experimental groups of 2 independent experiments. Two-way ANOVA, 
Bonferroni post-test (* P<0.05) 
 
5.5.5. Local injections of anti-CCL20 Ab slightly accelerate tumor growth B16-CCL20 injected 
CCR6-/- mice compared to controls. 
We performed reciprocal experiments with local injections of an anti-mCCL20 antibody (anti-mCCL20 Ab) 
in order to determine the effect of local CCL20 neutralization on tumor growth and incidence in Wt and 
CCR6-/- mice. The capability of the anti-mCCL20 Ab to neutralize B16-CCL20 derived mCCL20 was tested 
in vitro  before the in vivo experiment (Fig 15B). 
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We injected B16-CCL20 in Wt and CCR6-/- mice followed by local subcutaneous injections into the site of 
the tumor of anti-mCCL20 Ab every two days after tumor inoculation (Fig 15A). While not reaching 
statistical significance, we observed a slight increase in tumor growth during the last days of the 
experiment in CCR6-/- mice that had been administrated periodically anti-mCCL20 Ab in comparison to 
PBS injected CCR6-/-. Wt animals injected with PBS developed tumors slightly slower than their anti-
mCCL20 injected littermates while no reaching statistical significance. (Fig 15C).  
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Figure 15. Neutralizing mCCL20 slightly accelerates tumor growth inB16-CCL20 injected CCR6
-/-
 mice. 4x10
5
 cells 
of B16-CCL20 cells were injected s.c. in the flank of Wt and CCR6
-/-
 mice. Local intratumoral injections of anti-
mCCL20 Ab or PBS were provided every two days after tumor inoculation. Tumor growth was measured daily using 
a caliper. A. Illustrative scheme of the experimental set up. Two additional groups of Wt and CCR6
-/-
 mice were 
provided periodical injections of PBS after B16-CCL20 melanoma cell inoculation as a control B. anti-mCCL20 
antibody is able to neutralize B16-CCL20 derived mCCL20. B16-CCL20 supernatants were incubated at 37ºC for 1 h 
with and without anti-mCCL20. mCCL20 was measured by means of ELISA. Unpaired T-test (* P<0.05, ** P<0.005) 
C. Tumor growth from B16-CCL20 injected Wt and CCR6
-/-
 mice. Tumor area = (major radius)*(minor radius)*π. Two 
way ANOVA, Bonferroni post-test. Dots represent means ±SEM of 5 mice on each experimental group (** P<0.005)  
Day 2 Day 15 Day 0 
Anti-mCCL20 
periodical injections 
Wt mice 
CCR6 
-/-
 mice 
s.c. injection 
s.c. injection 
B16-CCL20 
A 
B C 
Results 
~ 77 ~ 
 
5.6. Characterization of tumor infiltrating leucocytes (TILs) in B16-Control/B16-
CCL20 melanoma tumors in Wt and CCR6-/- mice 
 
5.6.1. Aim and introduction 
As previous results indicated a role for the CCR6/CCL20 axis in melanoma, we set out to further 
characterize the immune cell infiltrate, in particular infiltrating CCR6+ leucocytes within tumors and DLN 
in our animal model (Scheme 2).  
 
Tumors were dissected from mice and immune cells were analyzed by FCM at two different time points: 
9 days after tumor injection (once solid tumors were established at an early growing stage) and 15 days 
after tumor injection coinciding with the end of the experiment, when big tumors (> 1 cm Ø) were 
robustly established (Scheme 3)  
 
Scheme 3. Illustrative figure showing experimental time points at which tumors got dissected and TILs were 
analyzed: Early (day 9 p.i.) and late (day 15 p.i.) stage tumors. 
 
5.6.2. FCM gating strategy and identification of CCR6+ TIL subsets 
We established two FCM gating panels that included different CCR6+ immune cell subsets alongside with 
other immune cell types known to have key roles in tumor progression and immunity. Due to 
experimental limitations it was not possible to functionally characterize all of them during each 
experiment and identification was phenotypically based on surface markers. Markers used to identify 
each subset are collected in Table 1. 
 
Within the B-cell fraction, our FCM panel was designed to identify activated B-cells, B1 and Killer B-cells, 
Memory B-cells and B-regulatory cells. Among these CCR6+ subsets have been described for activated B-
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cells [308], B-regulatory cells [309] and memory B-cells [308]. As for T-cells, our gating strategy included 
CD4+ and CD8+ fractions. Within CD4+ leucocyte subsets of T-regulatory and CD3+CD4+Foxp3- have 
been identified to express CCR6 [310]. On the other hand, no CD8+CCR6+ cells have been described in 
mice so far. However, given the key roles of CD8+ cells in tumor immunology [311] we decided to include 
this subset into our analysis. Regarding dendritic cells, we included plasmacytoid and myeloid types, of 
which CCR6+ subsets have been described [312]. Macrophages were also included in the final panel, as 
their role in melanoma is well described [259]. Our FCM gating strategy comprised two different panels 
based on the compatibility of the different detection antibodies used. Panel A included all B-cell subsets 
and CD8+ T-cells (Fig 16) while panel B included CD4+ T-cells, Dendritic cells and Macrophages. (Fig 17) 
 
Immune Cell 
type 
Subset Markers Reference 
B-cells           
   B-regs CD19+ CD45R+ CD5+   313 
  Activated B-cells CD19+ CD45R+ CD5-   314 
     - CCR6+ Act. B-cells CD19+ CD45R+ CD5- CCR6+ 
   Memory B-cells CD19- CD45R+ CD5-   314 
     - CCR6+ Memory B-cells CD19- CD45R+ CD5- CCR6+ 
   B1/K cells CD19- CD45R- CD5+   315 
     - CCR6+ B1/k cells CD19- CD45R- CD5+ CCR6+ 
 
T-cells   CD3+       
    CD8+ CD3+ CD8+     316 
  CD4+ CD3+ CD4+     317 
        - CCR6+ CD3+ CD4+ Foxp3 - CCR6+ 318 
        - T-regs CD3+ CD4+ Foxp3+ CCR6- 319 
             -CCR6+ T-regs CD3+ CD4+ Foxp3+ CCR6+ 320 
DCs   CD11c+       321 
  pDCs CD11c+ CD45R+     322 
     - CCR6+ pDCs CD11c+ CD45R+ CCR6+   
   cDCs CD11c+ CD45R-     323 
     - CCR6+ cDCs CD11c+ CD45R- CCR6+   
 
Macrophages   CD11c
low
 CD45R-     324 
 
Table 1. Surface markers and phenotypical characterization of immune cell subsets. 
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Figure 16. Overview of gating panel A. B-cell subsets (Memory B-cells, Activated B-cells, B1/K cells and 
B-regulatory cells) and CD8+ T-cells. Each subset was subsequently gated for CCR6+ signal. 
 
Figure 17. Overview of gating panel B. CD4+ T-cells (including T-regulatory cells), Dendritic cells (pDCs 
and cDCs) and Macrophages. Each subset was subsequently gated for CCR6+ signal. 
Gating panel B (CD4+ T-cells, DCs and Macrophages) 
Gating panel A (B-cells and CD8+ T-cells) 
CD4+CCR6+ 
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5.6.3. Characterization of TILS 
5.6.3.1. B-cells  
5.6.3.1.1. Activated B-cells (CD19+CD45R+CD5-) 
  Both Wt experimental groups showed low levels of activated B-cells at early and late 
time points regardless of the melanoma cell line injected. Interestingly, B16-Control injected CCR6-/- mice 
showed significantly higher levels of infiltrating active B-cells than B16-CCL20 injected CCR6-/- animals. 
Nevertheless, by day 15 activated B-cell infiltrate in this group had decreased to the same values of the 
B16-CCL20 group (Fig 18B) 
  
5.6.3.1.2. Memory B-cells (CD19-CD45R+CD5-) 
  No significant differences were found in the amount of infiltrating Memory B-cells 
between the experimental groups from Wt and CCR6-/- animals. Interestingly, levels of this immune cell 
subset were slightly higher at day 15 in B16-CCL20 injected CCR6-/- (Fig. 18C) 
 
5.6.3.1.3. Regulatory B-Cells (B-regs) (CD19+CD45R+CD5+) 
  Levels of B-regs were significantly higher at day 9 in B16-CCL20 injected CCR6ko-/- mice. 
This contrasts with low number of infiltrating B-regs in Wt experimental groups and B16-Control CCR6-/- 
group at both analyzed time points. (Fig. 18D) 
 
5.6.3.1.4. B1/K cells (CD19-CD45R-CD5+) 
  With the exception of B16-Control injected Wt mice, B1/K cell levels decreased from day 
9 to day 15 in the rest of the groups. No significant differences in B1/K cell infiltrate were detected 
between experimental groups (Fig 18E). 
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Figure 18. B-cell TILs subsets at early and late tumor growth stages. Tumors were dissected from Wt and CCR6
-/-
 
animals injected either with B16-Control or B16-CCL20 melanoma cells after 9 or 15 days after inoculation. After 
dissection and digestion the immune fraction was isolated by Percoll gradient and leucocytes were identified by 
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means of FCM analysis. A. Activated B-cells. B. Memory B-cells. C. B-regulatory cells (B-regs). D. B1 and Killer B-
cells. Data was obtained from three independent experiments (n=15 mice). Values are expressed as mean ±SEM. 
Two-way ANOVA, Bonferroni post-test (** P<0.005, *** P<0.0005) 
5.6.3.2. T-cells (CD3+) 
We observed increased amounts of infiltrating T-cells within the tumors of CCR6-/- mice when 
compared to Wt mice at day 9 after tumor inoculation. While T-cell levels from B16-CCL20 injected CCR6-
/- mice were significantly higher than B16-Control injected animals in this time point, by day 15 the 
amount of T-cells decreased drastically (Fig 19A). 
 
5.6.3.2.1. CD8+ T-cells (CD3+CD8+) 
No significant differences were found in the amount of infiltrating CD8+ T-cells between 
the experimental groups from Wt and CCR6-/- animals. Total amounts of this T-cell subset were 
considerably low over time (Fig 19B). 
 
5.6.3.2.2. CD4+ T-cells (CD3+CD4+) 
While levels of infiltrating CD4+ T-cells in Wt mice were as low as CD8+ cells at both time 
points analyzed, we observed highly significant amounts of CD4+ cells in CCR6-/- at day 9, decreasing 
dramatically by day 15. Interestingly, within both CCR6-/- experimental groups, B16-CCL20 mice showed 
significantly higher infiltrating CD4+ cells than their B16-Control counterparts (Fig 19C). 
5.6.3.2.2.1. Regulatory T-cells (T-regs) (CD3+CD4+Foxp3+) 
  In line with our observations concerning total amount of infiltrating CD4+ T-cells, 
T-reg levels were significantly higher in the CCR6-/- experimental groups at day 9 time point compared 
with their Wt counterparts, decreasing afterwards. In this case, however, there were no significant 
differences between both experimental groups. Infiltrating T-reg levels in Wt were low at both time 
points (Fig 19D). 
 
 
  
Results 
~ 83 ~ 
 
Tumor infiltrating T-cell subsets 
CD3+ T-cells Wt
Day 9 Day 15
0
100
200
300
400
500
d.p.i.
B16-CCL20
B16-Control
n.s.
n.s.
L
iv
e
 c
e
ll
s
/m
m
2
 T
u
m
o
r
CD3+ T-cells CCR6 -/-
Day 9 Day 15
0
100
200
300
400
500
d.p.i.
B16-CCL20
B16-Control**
n.s.
L
iv
e
 c
e
ll
s
/m
m
2
 T
u
m
o
r
 
CD8+ T-cells Wt
Day 9 Day 15
0
10
20
30
40
B16-Control
d.p.i.
B16-CCL20
n.s.
n.s.
L
iv
e
 c
e
ll
s
/m
m
2
 T
u
m
o
r
CD8+ T-cells CCR6-/-
Day 9 Day 15
0
10
20
30
40
B16-Control
d.p.i.
B16-CCL20
n.s.
n.s.
L
iv
e
 c
e
ll
s
/m
m
2
 T
u
m
o
r
 
CD4+ T-cells Wt
Day 9 Day 15
0
100
200
300
400
d.p.i.
B16-CCL20
B16-Control
n.s n.s
L
iv
e
 c
e
ll
s
/m
m
2
 T
u
m
o
r
CD4+ T-cells CCR6
-/-
Day 9 Day 15
0
100
200
300
400
d.p.i.
B16-CCL20
B16-Control
**
n.s
L
iv
e
 c
e
ll
s
/m
m
2
 T
u
m
o
r
 
T-regs Wt
Day 9 Day 15
0
10
20
30
40
50
d.p.i.
B16-Control
B16-CCL20
n.s.
n.s.
L
iv
e
 c
e
ll
s
/m
m
2
 T
u
m
o
r
T-regs CCR6-/-
Day 9 Day 15
0
10
20
30
40
50
d.p.i.
B16-Control
B16-CCL20
n.s.
n.s.
L
iv
e
 c
e
ll
s
/m
m
2
 T
u
m
o
r
 
Figure 19. Levels of T-cell TIL subsets at early and late tumor growth stages. Tumors were dissected from Wt and 
CCR6
-/-
 animals injected either with B16-Control or B16-CCL20 melanoma cells after 9 or 15 days after inoculation. 
After dissection and digestion the immune fraction was isolated by Percoll gradient and leucocytes were identified 
A 
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by means of FCM analysis. A. Total T-cell number. B. CD8+ T-cells. C. CD4+ T-cells. D. T-regulatory cells (T-regs). 
Data was obtained from three independent experiments (n=15 mice). Values are expressed as mean ±SEM. Two-
way ANOVA, Bonferroni post-test (** P<0.005, *** P<0.0005) 
5.6.3.3. Dendritic cells 
5.6.3.3.1. Conventional Dendritic cells (cDCs) (CD11c+CD45R-) 
  No significant differences were found between experimental groups within Wt or CCR6-/- 
animals. At day 9 however, levels of infiltrating cDCs were significantly higher in both CCR6-/- groups 
compared to their Wt counterparts (Fig 20A). 
 
5.6.3.3.2. Plasmacytoid Dendritic cells (pDCs) (CD11C+CD45+) 
  Infiltrating rate of pDCs was weak or non-existent at analyzed time points in both CCR6-/- 
experimental groups and in B16-CCL20 injected Wt animals. Interestingly, levels of pDCs were 
significantly higher in B16-CCL20 inoculated Wt mice at day 9 (Fig 20B). 
 
5.6.3.4. Macrophages (CD11clowCD45R-) 
 Infiltrating macrophage rate was significantly higher in CCR6-/- experimental groups at day 9 time 
point compared to the Wt groups, whose macrophage amounts within the tumor kept more or less 
constant over time regardless of the melanoma cell line injected. At day 15 macrophage levels in the 
tumor of CCR6-/- mice decreased considerably (Fig 20C). 
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Figure 20.  Tumor infiltrating Dendritic cells and Macrophages at early and late tumor growth stages. Tumors 
were dissected from Wt and CCR6
-/-
 animals injected either with B16-Control or B16-CCL20 melanoma cells after 9 
or 15 days after inoculation. After dissection and digestion the immune fraction was isolated by Percoll gradient 
and leucocytes were identified by means of FCM analysis. A. Conventional Dendritic cells (cDCs). B. Plasmacytoid 
Dendritic Cells (pDCs). C. Macrophages. Data was obtained from three independent experiments (n=15 mice). 
Values are expressed as mean ±SEM. Two-way ANOVA, Bonferroni post-test (** P<0.005, *** P<0.0005) 
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5.6.3.5. CCR6+ TILs in Wt mice 
Throughout the analysis of TILs in B16-Control and B16-CCL20 injected Wt mice we detected 
CCR6+ subsets within CD4+ T-cells, T-regulatory, conventional DCs and plasmacytoid DCs. No CCR6+ 
infiltrate was detected in CCR6-/- mice (data not shown). 
 
5.6.3.5.1. CD4+ CCR6+ T-cells  
  CD4+CCR6+ T-cell levels were significantly higher within tumors from B16-Control 
injected Wt mice at day 9, decreasing drastically at day 15. B16-CCL20 injected animals kept low levels of 
this CCR6+ immune cell subset (Fig 21A). 
 
5.6.3.5.2. CCR6+ T-regs  
  Although infiltrating CCR6+ T-regulatory cell levels were similar at day 9 on both 
experimental groups, we observed a slightly significant increase at day 15 after tumor cell inoculation in 
B16-CCL20 injected mice (Fig 21B). 
 
5.6.3.5.3. CCR6+ cDCs and pDCs 
  Regarding dendritic cells, we found significantly higher amounts of CCR6+ cDCs and pDCs 
in B16-Control injected groups at day 9 after tumor inoculation, followed by a considerable decrease by 
day 15. On the contrary, B16-CCL20 injected Wt animals showed relatively low levels of this infiltrating 
CCR6+ DC subsets (Fig 21C). 
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Figure 21.  Tumor infiltrating CCR6+ cell subsets in B16-Control and B16-CCL20 injected Wt mice. Tumors were 
dissected from Wt animals injected either with B16-Control or B16-CCL20 melanoma cells after 9 or 15 days after 
inoculation. After dissection and digestion the immune fraction was isolated by Percoll gradient and leucocytes 
were identified by means of FCM analysis. A. CD4+CCR6+ T-cell fraction, including CD4+CCR6+ cells. B. CCR6+ T-
regulatory cells. C. CCR6+ Conventional Dendritic cells. D. CCR6+ plasmacytoid Dendritic cells. Data was obtained 
from three independent experiments (n=15 mice). Values are expressed as mean ±SEM. Two-way ANOVA, 
Bonferroni post-test (** P<0.005, *** P<0.0005)  
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5.7. Ratios between TILs 
5.7.1. Aim and introduction 
In recent years, the importance that the balance between pro- and anti-tumor leukocytes has over 
tumor growth, promotion and regression has gained much attention. Several clinical studies have 
endorsed the hypothesis that ratios between different subsets can be good predictors of tumor 
prognosis. Most used ratios are CD8+/CD4+ (effector/helper), CD8+/Foxp3+ (effector/regulatory) and 
CD8+/pDCs (effector/suppressor) [325]. 
 
These three ratios were analyzed using data from the experiments described in section 5.6 in order to 
obtain a more comprehensive view of the events within the tumor. 
 
5.7.2. CD8+/CD4+ Ratio 
 All four experimental groups showed low ratios of CD8+/CD4+ at day 9. By day 15 however, Wt 
mice had significantly higher CD8+/CD4+ ratios than CCR6-/- animals. These differences were a bit higher 
in B16-CCL20 injected Wt mice, although not statistically different from B16-Control injected Wt animals 
(Fig 22A). 
 
5.7.3. CD8+/Foxp3+ Ratio 
 The ratio of CD8+ cells to Foxp3+ cells was low in CCR6-/- mice at both analyzed time points. In 
case of the Wt experimental groups, the ratios increased significantly by day 15. While no differences 
were observed between Wt groups at this time point in CD8+/Foxp3+ratios, they were significantly 
higher than in CCR6-/- animals (Fig 22B) 
 
5.7.4. CD8+/pDCs Ratio 
 The CD8+/pDCs ratio increased dramatically in B16-CCL20 injected Wt mice by day 15. B16-
Control injected Wt mice and both CCR6-/- experimental groups showed reduced values for this ratio at 
both analyzed time points during the experiment (Fig 22C)   
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Figure 22. Leucocyte subset ratios in B16-Control and B16-CCL20 injected Wt and CCR6
-/-
 mice. A. CD8+/CD4+ 
ratio. B. CD8+/Foxp3+ ratio. C. CD8+/pDCs ratio. Data taken from experiments described in 3.5. Values are 
expressed as mean ±SEM. Two-way ANOVA, Bonferroni post-test. 
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5.8. Characterization of the immune cell composition of tumor draining Lymph 
nodes (TDLN) from B16-Control/B16-CCL20 injected Wt and CCR6-/- mice 
 
5.8.1. Aim and introduction 
In addition to the characterization of the TILs, we were also interested in possible variations in the 
composition of these immune cell subgroups within the TDLN that could help us to understand the 
dynamics of the response from the immune system throughout the different stages of tumor 
progression. It has been described in previous studies that tumor-derived chemokines can be detected in 
the DLN [326], thus modulating the immune cell composition within [327]. 
 
Following this idea we established three different time points to analyze the composition of the DLNs in 
B16 injected mice: An early time point (4 days after tumor inoculation), a second time point (9 days after 
tumor inoculation) when solid tumors have been established, and a late time point at day (15 days after 
tumor inoculation) at the end of the experiment (Scheme 4). 
 
Scheme 4. Illustrative scheme showing experimental time points at which tumors got dissected and TILs were 
analyzed: Early (day 9 p.i.) and late (day 15 p.i.) stage tumors. 
 
FCM gating strategy and identification of the different immune cell subsets described in this section was 
performed following the same procedure as in section 5.6. 
 
Prior to this experiment, we characterized the inguinal LN immune cell composition from Wt and CCR6-/- 
individuals under homeostatic conditions (i.e. in the absence of a tumor) to ensure that there were no 
significant differences in the proportion of any of the selected leucocyte subsets (Fig. 23) 
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Figure 23. CCR6
-/-
 immune cell proportions in the LNs do not differ from Wt mice under homeostatic conditions. 
LNs were dissected from Wt and CCR6
-/-
 mice under homeostatic conditions. After mechanical disruption immune 
cell fraction was isolated and leucocytes were identified by means of FCM analysis. CCR6+ fraction of Wt mice 
derived cells is indicated as a superimposed bar graph. Each bar represents data taken from independent analysis 
of 10 mice in each group. Values are expressed as mean ±SEM. Two-way ANOVA, Bonferroni post-test. A. B-cell 
subsets B. T-cell subsets. C. Dendritic cells and Macrophages.   
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5.8.2. B-cells.  
5.8.2.1. Activated B-cells (CD19+CD45R+CD5-) 
With the exception of B16-Control injected CCR6ko mice, all experimental groups showed a slight 
increase on the proportion of activated B-cells that dropped significantly by day 15. However, the 
relative amounts of this immune cell subset were significantly similar in all experimental groups. In the 
case of CCR6-/- mice this contrasts with our previous findings, where we detected significantly increased 
amounts of this cells infiltrating the tumor at day 9 (Fig. 24A). 
 
5.8.2.2. Memory B-cells (CD19-CD45R+CD5-) 
The proportion of this B-cell subset in the draining LN decreased slightly compared to healthy individuals 
and remained constant as long as the experiment lasted. As we commented previously, we observed 
small amounts of Memory B-cells within the tumor by day 15 (Fig. 24B). 
 
5.8.2.3. Regulatory B-Cells (B-regs) (CD19+CD45R+CD5+) 
As in the case of Memory B-cells, the proportion of B-regs within the LN remained more or less constant 
over time and no significant differences were observed between the experimental groups. Interestingly, 
while no tumor infiltrating B-regs were detected on B16-CCL20 injected CCR6-/- animals by day 9, we 
observed a discrete increase of these cells within tumors from their B16-Control injected counterparts 
(Section 5.6.3.1.3)  (Fig. 24C). 
 
5.8.2.4. B1/K cells (CD19-CD45R-CD5+) 
No differences in the proportion of B1/cells were observed in the lymph nodes of CCR6-/- experimental 
groups. In the case of Wt mice, both experimental groups showed similar amounts of this B-cell subset at 
early (day 4) and late (day 15) time points (Fig. 24D). However, B16-CCL20 injected Wt mice showed a 
significant increase on the proportion of B1/K cells by day 9. Interestingly, our analysis of TILs showed 
slightly higher amounts of these leucocytes in this experimental group as well (Section 5.6.3.1.4), 
although these differences were not statistically significant 
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Figure 24. Percentage of B-cell subsets over time in TDLN from Wt and CCR6
-/-
 mice. LNs were dissected from Wt and CCR6
-/-
 
animals injected either with B16-Control or B16-CCL20 melanoma cells after 4, 9 or 15 days after inoculation. After mechanical 
disruption immune cell fraction was isolated and leucocytes were identified by means of FCM analysis.. A. Activated B-cells. B. 
Memory B-cells. C. B-regulatory cells (B-regs). D. B1 and Killer B-cells. Data was obtained from three independent experiments 
(n=15 mice). Values are expressed as mean ±SEM. Two-way ANOVA, Bonferroni post-test (* P<0.05) 
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5.8.3. T-cells (CD3+) 
Although no significant differences were detected within CCR6-/- and Wt experimental groups, we 
observed that amount of total T-cells in B16-CCL20 injected animals behaved similarly over time, in 
contrast with B16-Control groups which relative amounts of this immune cell type fluctuated more.  
 
It is to be mentioned that while B16-CCL20 injected CCR6-/- mice showed significantly higher amounts of 
T-cells infiltrating their tumors, this was not reflected in changes in relative amounts of this immune cell 
type in the lymph nodes in comparison with their B16-Control injected counterparts (Fig. 25A). 
 
5.8.3.1. CD8+ T-cells (CD3+CD8+) 
All four experimental groups had same relative amounts of CD8+ T-cells at all analyzed time points. As 
we commented previously, no significant differences in the amount of this T-cell subset were detected 
among TILs as well.  In all cases the proportion of CD8+ T-cells increased significantly at day 9 after tumor 
inoculation, remaining at normal levels the rest of the time (Fig. 25B). 
 
5.8.3.2. CD4+ T-cells (CD3+CD4+) 
With the exception of a slight increase on the amount of CD4+ T-cells at the lymph nodes from B16-
CCL20 injected CCR6-/- mice at day 4, proportions of these immune cells remained at similar amounts in 
all four experimental groups at all analyzed time points (Fig. 25C). Interestingly, although we detected 
higher amounts of tumor infiltrating CD4+ T-cells ad day 9 in CCR6-/- mice, the relative amounts of this T-
cell subset were similar between Wt and CCR6-/- experimental groups (Section 5.6.3.2.2). 
5.8.3.2.1. T-regulatory cells (T-regs) (CD3+CD4+Foxp3+) 
Relative amounts of T-regs increased in all experimental groups after tumor inoculation. However, while 
this proportion decreased progressively over time in all groups, B16-CCL20 injected Wt animals kept 
constant levels of this T-cell subset.  
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Figure 25. Percentage of T-cell subsets over time in TDLN from Wt and CCR6
-/-
 mice. LNs were dissected from Wt and CCR6
-/-
 
animals injected either with B16-Control or B16-CCL20 melanoma cells after 4, 9 or 15 days after inoculation. After mechanical 
disruption immune cell fraction was isolated and leucocytes were identified by means of FCM analysis. A. Total T-cell number. B. 
CD8+ T-cells. C. CD4+ T-cells. D. T-regulatory cells (T-regs). Data was obtained from three independent experiments (n=15 mice). 
Values are expressed as mean ±SEM. Two-way ANOVA, Bonferroni post-test. 
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5.8.4. Dendritic cells 
5.8.4.1. Conventional Dendritic cells (cDCs) (CD11c+CD45R-) 
No significant differences were observed in the proportion of cDCs between the four experimental 
groups, although fluctuations over time were slightly different depending on the mice strain and the cell 
line injected. Our observations of infiltrating cDCs showed no significant differences between groups as 
well, although CCR6-/- animals presented higher levels of this immune cell subset at day 9 (Fig. 26A). 
 
5.8.4.2. Plasmacytoid Dendritic cells (pDCs) (CD11C+CD45+) 
  The proportion of pDCs in B16-Control experimental groups increased significantly 
compared to their B16-CCL20 counterparts at day 4. Despite these early differences, the proportion of 
pDCs at days 9 and 15 was similar in all four experimental groups. Interestingly, although amounts of this 
immune cell subset fluctuated in the same way within the Lymph nodes of B16-Control injected Wt and 
CCR6-/-, we observed an increase of tumor infiltrating pDCs only in the Wt group (Fig. 26B). 
 
5.8.4.3. Macrophages (CD11clowCD45R-) 
 No significant differences were detected between all four experimental groups in the proportion 
of macrophages within the DLN. In all cases the relative amount of macrophages decreased compared to 
healthy conditions (Fig. 26C). 
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Figure 26. Proportion of Dendritic-cells/Macrophages in TDLN from Wt and CCR6
-/-
 mice over time. LNs were 
dissected from Wt and CCR6
-/-
 animals injected either with B16-Control or B16-CCL20 melanoma cells after 4, 9 or 
15 days after inoculation. After mechanical disruption immune cell fraction was isolated and leucocytes were 
identified by means of FCM analysis. A. conventional Dendritic cells (cDCs). B. plasmacytoid Dendritic cells (pDCs). 
Data was obtained from three independent experiments (n=15 mice). Values are expressed as mean ±SEM. Two-
way ANOVA, Bonferroni post-test. (* P<0.05). 
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5.8.5. CCR6+ immune cell subset composition of TDLN from B16-Control/B16-CCL20 injected 
Wt mice 
While the infiltrating CCR6+ immune cell subsets were limited to CD4+ T-cells and dendritic cells, within 
the lymph node we detected a bigger array of leucocyte types expressing this receptor. In addition to the 
previously commented, we detected different types of B-cells (Activated, B1/K and memory B-cells) and 
Macrophages. Interestingly, no CCR6+ cDCs were detected on the lymph nodes.  
 
5.8.5.1. CCR6+ Activated B-cells 
  Levels of CCR6+ Activated B-cells decreased drastically at day 9 and increased 
significantly by day 15 in both Wt experimental groups. However, no significant differences were 
detected between B16-Control and B16-CCL20 injected mice (Fig. 27A). 
  
5.8.5.2. CCR6+ B1/K cells 
  CCR6+ B1/K cell proportion increased progressively till day 9 and decreased slightly by 
day 15, coming back to the values of healthy individuals. As in the case of Memory B cells, no significant 
differences were found between both Wt experimental groups (Fig. 27B). 
 
5.8.5.3. CCR6+ Memory B-cells 
  The proportion of CCR6+ Memory B-cells within the Lymph node decreased drastically at 
day 4 after tumor inoculation compared to healthy conditions. The relative amounts of these immune 
cell subsets increased slightly by day 9. This phenomenon was observed in both B16-Control and B16-
CCL20 injected Wt mice (Fig. 27C). 
 
5.8.5.4. CD4+ CCR6+ T-cells 
  The amount of CD4+CCR6+ T-cells increased drastically in the lymph node at day 4 
compared to healthy conditions. However, while in B16-Control injected mice the proportion of this T-
cell subset kept decreasing progressively, the relative numbers of CD4+CCR6+ T-cells found in B16-CCL20 
injected animals were significantly higher by day 15 (Fig. 27D). 
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5.8.5.5. CCR6+ T-regs 
  The proportion of CCR6+ T-regs was constant over time after tumor inoculation. 
However, we observed significant increase of this cell subset in B16-CCL20 injected Wt mice by day 15 
(Fig. 27E).  
5.8.5.6. CCR6+ pDCs 
  Levels of CCR6+ pDCs decreased drastically after tumor inoculation in both Wt 
experimental groups. Despite a slight increase on the amount of this cell subset in B16-Control injected 
animals around day 9, no significant differences were detected between the groups while the 
experiment lasted (Fig. 27F). 
 
5.8.5.7. CCR6+ Macrophages 
  Similar to CCR6+ pDCs, the relative amounts of macrophages within the DLN of Wt 
animals decreased drastically compared to healthy conditions and kept low levels until the end of the 
experiments. Injection of B16-Control or B16-CCL20 cells created no observable differences in the 
proportion of this immune cell subset (Fig. 27G). 
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Figure 27. Proportion of CCR6+ immune cell subsets at TDLNs from Wt and CCR6
-/-
 mice over time. LNs were dissected from 
Wt and animals injected either with B16-Control or B16-CCL20 melanoma cells after 4, 9 or 15 days after inoculation. After 
mechanical disruption immune cell fraction was isolated and leucocytes were identified by means of FCM analysis. A. CCR6+ 
Activated B-cells. B. CCR6+ B1/K B-cells. C. CCR6+ Memory B-cells. D. CCR6+ CD4+ T-cells. E. CCR6+ T-regulatory cells. F. CCR6+ 
pDCS. G. CCR6+ Macrophages Data was obtained from three independent experiments (n=15 mice). Values are expressed as 
mean ±SEM. Two-way ANOVA, Bonferroni post-test (*P<0.05) 
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5.9. Characterization of the inflammatory cytokine composition of B16-
Control/B16-CCL20 tumors arising in Wt and CCR6-/- mice  
 
5.9.1. Aim and introduction 
The presence or absence of certain cytokines in the microenvironment can affect the immune system 
acting directly over the leucocytes, or indirectly by modifying the conditions of the tumor 
microenvironment [328]. The absence of proper chemoattractants or immune cell activators within the 
tumor may hamper the migration and/or activation of certain immune cells. It has been observed that 
the immune effector function can be inhibited by suppressor factors secreted by tumor cells [329]. In 
this context, variations in the concentration of CCL20 at the site of a growing tumor may affect the 
cytokine composition of the tumor microenvironment.  
 
This part of the project sought to analyze the composition of soluble components of the tumor 
microenvironment in B16 injected experimental animals in order to detect possible imbalances in the 
levels of 13 different murine cytokines: IL-23, IL-1α, IFN-ɣ, TNF-α, CCL2, IL12p70, IL-10, IL-9, IL-6, IL-27, IL-
17α, IL-22 and TSLP 
 
5.9.2. Proportion of IFN-ɣ within the tumor microenvironment is significantly lower in B16-
CCL20 injected CCR6-/- mice  
Supernatants from dissected and digested tumors of B16-Control and B16-CCL20 injected Wt and CCR6-/- 
were extracted and analyzed the following day by means of LEGENDPLEX assay (Fig 28A) 
 
Data was normalized to tumor size. We observed no significant differences in the levels of the majority 
of cytokines between the four experimental groups. However, B16-CCL20 CCR6-/- mice showed 
significantly lower levels of IFN-ɣ when compared to Wt groups and B16-Control injected CCCR6-/- 
animals (Fig 28B)  
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Figure 28. Pro-inflammatory composition of the tumor microenvironment from B16-Control and B16-CCL20 
injected Wt and CCR6
-/-
 mice. Solid tumors were dissected at day 15 after B16 cell injections. Tumors were 
digested and cytokine composition from the supernatants was analyzed by means of LEGENDPLEX. A. General 
overview in form of heatmap from the 13 different cytokines identified (bottom). Rows represent different 
individuals from each experimental group. Data was normalized to individual tumor size. B. Concentration of IFN-ɣ 
per tumor mm
2
. No significant differences were observed for the remaining 12 cytokines described. Unpaired T-test 
(* P<0.05). 
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5.10. Autocrine signaling pathway in melanoma cells. 
 
5.10.1. Aim and introduction 
As shown in previously, we found that overexpression of CCL20 by B16 cells resulted in a significant 
reduction in tumor progression in CCR6-/- mice. Besides possible effects in the tumor microenvironment, 
we wanted to study if CCL20 could affect B16-cells in an autocrine manner. Since the different B16 
murine melanoma cell lines used in our experiments were CCR6+/+, the aim of this part of the project was 
to assess whether they could be expressing CCR6, since they could be the only CCR6+ bearing cells in 
these animals (Scheme 5).  
 
 
 
 
 
 
 
Scheme 5. Illustrative scheme of CCR6
+/+
 B16 melanoma cells of possible autocrine signaling of CCL20 on CCR6 
expressing melanoma cells in CCR6
-/-
 mouse skin. 
 
5.10.2. B16-CCL20 cells express CCR6 in vitro  
We analyzed CCR6 expression by means of FCM under homeostatic conditions in our different 
melanoma cell lines B16-Control, B16-CCL20 and their parental B16 cell line. Our results showed that 
while B16-parental and B16-Control cells had weak/non-existent expression of CCR6, B16-CCL20 cells 
showed significant expression of the chemokine receptor (Fig 29) 
  
CCR6+/+ B16 cells 
CCR6+/+ B16 cells 
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Fig. 29. B16-CCL20 cells express CCR6 in vitro .  B16-Control, B16-CCL20 and B16-parental Cells were cultured in 24-
well plates for 48h under homeostatic conditions and CCR6 expression was measured by means of FCM. Yellow. 
APC-isotype control signal. Blue. APC-CCR6 antibody signal. 
 
5.10.3. rCCL20 does not affect the proliferation capacity of B16-CCL20 and B16-Control cells in 
vitro  
In order to test if recombinant murine CCL20 (rCCL20) may affect the proliferation of our retrovirally 
transduced cell lines we cultured B16-Control and B16-CCL20 in presence of rCCL20 and measured 
proliferation after 24 and 48h by means of XTT. Results showed that presence of rCCL20 in the medium 
had no effect in proliferation when compared to control conditions in both cell lines (Fig. 30). 
 
 
 
 
 
 
 
 
Fig 30. CCL20 stimulation does not modify proliferation capability of B16-Control and B16-CCL20 cell lines. Results 
of XTT proliferation assay from B16-CCL20 and B16-Control cells under control and CCL20 stimulation conditions for 
24 and 48 hours. Bar graphs show mean ±SD from two independent experiments. 
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5.10.4. rCCL20 reduces expression of certain cytokines of by B16-CCL20 and B16-Control cells 
in vitro  
We analyzed the cytokine composition of supernatants from B16-Control and B16-CCL20 cells cultured in 
presence or absence of rCCL20 and compared them with the original B16 parental cell line by means of 
Legendplex. High concentrations of rCCL20 were able to downregulate the expression of some cytokines 
(such as TNF-α, Il-10, IL-9 and IL-27) in the three cell lines (Fig 31).  
 
5.10.5. Stimulation with rCCL20 increases wound healing ratio of B16-CCL20 but not B16-
Control melanoma cells in vitro  
The effect of rCCL20 on the migratory capability of B16-CCL20 and B16-Control was tested by means of 
wound healing assay. Under homeostatic conditions, unstimulated B16-CCL20 showed higher wound 
healing ratios than B16-Control cells. Further, an in support of an effect of autocrine CCR6/CCL20 
interaction the wound healing ratio of CCR6+ B16-CCL20 increased significantly 24h after wound scratch 
in the presence of high concentrations of rCCL20. However, the presence of rCCL20 did not alter the 
migration capability of CCR6- B16-Control cells (Fig 32). 
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Figure 31. B16-Control and B16-CCL20 respond in the same way to CCL20 and TNF-α stimulation in terms of 
cytokine expression. B16, B16-Control and B16-CCL20 cells were cultured with and without CCL20 and TNF-α 
stimulation for 48h. Supernatants were collected and concentrations of 13 different murine pro-inflammatory 
cytokines were measured by means of LEGENDPLEX. A. Expression with and without different concentrations of 
rCCL20. B. Expression with and without different concentrations of TNF-α 
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Figure 32. Wound healing rates of B16-Control and B16-CCL20 cells. Bar graphs show mean ±SD from three 
independent experiments. Student T-test (*P<0,05). 
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6. DISCUSSION 
 
Melanoma tumor initiation, growth and metastasis are regulated by a series of chemokine-controlled 
mechanisms and various chemokine axes have been studied as potential therapeutic targets for the 
control of melanoma [330,331,332]. In this context, the CCR6/CCL20 axis is an attractive target due to 
the mutual exclusivity of CCL20 and CCR6. However, and despite promising results obtained during the 
study of this chemokine axis in other types of cancer, the precise role of CCR6 and CCL20 in melanoma 
pathogenesis is still a matter of controversy.  
 
To quote an example of this dissonancy, in 2016 Matsuo and collaborators focused on the impact of 
CCR6-deficiency on antitumor immunity using a subcutaneous B16 injection model finding no differences 
between Wt and CCR6-/- mice in terms of tumor progression, relative amounts of TILs and TDLN 
leucocyte composition [300]. Two years later Samaniego and his group described a relation between 
CCL20 expressing tumor infiltrating macrophages and poor tumor prognosis [141]. The fact that CCR6 is 
expressed in a huge array of immune cells with very diverse functions, together with the fact that several 
kinds of cells are able to secrete CCL20 originates most of these controversies.  
 
Groups like the mentioned above have emulated CCL20-deficiency conditions by using anti-CCL20 
antibodies to regionally hamper the interactions of this chemokine with its environment. However, while 
examples like this make a good approach, still leave some loopholes open. First, CCL20 is expressed 
under homeostatic conditions by several tissues [97]. Blocking this chemokine in certain anatomical 
locations might modify the chemotactic gradient, thus influencing on the migration of certain immune 
cells towards surrounding tissues. Second, since CCL20 can come from different sources within the 
tumor (such as tumor cells, stromal components, TILs), CCL20 decrease may trigger its expression in any 
of these components by autocrine or paracrine feedback loops. Further, CCR6+ subsets have been 
described among both, immune cell types that drive the activation and those that mediate down-
regulation of immune responses. 
 
To illustrate the dilemma derived from this experimental models for chemokine-axes we can take a look 
at CCR7 in cancer. When expressed by B16 cells, CCR7 increases tumorigenecity and metastatic rate of 
melanoma tumors in mice. However, when expressed by tumor infiltrating dendritic cells, these immune 
cells migrate towards regional lymph nodes and activate cytotoxic CD8+ T-cells, resulting in a strong anti-
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tumor response [270]. Hence, treating melanoma tumors with CCR7 blockers/inhibitors will not result in 
a clear predictable outcome. 
 
Complementing previous studies, in this project we made a combined approach of both CKR-knock out 
animals and local over- and under-expression of the chemokine at the tumor site to clarify the role of the 
CCR6/CCL20 axis in melanoma tumor progression. In addition to the study of CCR6 deficiency using CCR6-
/- animals we have focused on the characterization of the effects of tumor derived CCL20 in melanoma 
pathogenesis and progression. 
 
6.1. In vitro characterization of CCL20 expression in human and murine melanoma 
cell lines under homeostatic and inflammatory conditions 
Unlike the majority of chemokines, CCL20 can be expressed under both homeostatic and inflammatory 
conditions. In the skin, its antimicrobial properties support the skin’s barrier function against occasional 
bacterial infections [333]. Under homeostatic conditions CCL20 is expressed in the skin mainly by 
keratinocytes [334]. On the other hand, upon inflammatory conditions CCL20 is overexpressed in the 
epidermis functioning as a chemo-attractant for CCR6+ immune cells. This mechanism has been 
described as a major pathogenic factor in inflammatory skin diseases such as psoriasis [162]. 
 
CCL20 expression by human melanocytes upon inflammatory stimuli has been described as well [335]. In 
melanoma, various groups have reported inducible expression of CCL20 by tumor cells [297]. 
 
In line with these observations, we have observed that under homeostatic conditions in vitro  CCL20 
expression is weak or non-existent, but could be triggered under stimulation with pro-inflammatory 
cytokines such as TNF-α or IL1-α in both the murine and human melanoma cell lines we tested.  
 
TNF-α and IL1-α are found at high concentrations within the tumor microenvironment, thus potentially 
facilitating migration of CCR6+ immune cells towards CCL20 expressing tumors. Nevertheless, in vitro 
conditions may not properly reflect how these cells would behave in vivo. The cytokine milieu within the 
tumor microenvironment comprises many different factors, and CCL20 expression by tumor cells could 
vary depending on the combination of these. For instance, it has been reported that TGF-β, a cytokine 
reported to be present in melanoma tumors [336] downregulates CCL20 expression [337]. 
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6.1.1. Loss of chemokine expression in vitro or the “passage effect” 
In vitro CCL20 production capability of human and murine melanoma cells decreased progressively over 
passages up to a point where stimulation with pro-inflammatory cytokines like mTNF-α could not trigger 
its expression anymore.  
 
It has been reported that in vitro  culture conditions may modify the expression of several genes over 
time [338] and cells that have been overly cultured show malfunctions, reduced proliferation or get 
senescent [305,339]. In our case, loss of CCL20 expression capability started to take place after a few 
passages. 
 
Collaborator Professor Fran Balkwill from the Barts Cancer institute in London had been experiencing 
similar phenomena in different cell lines regarding the expression of several cytokines/chemokines, and 
suggested the use of early passaged cells for experimental use. Reasons of chemokine expression loss 
over time are not yet well understood. Some groups like Pivarcsi and collaborators have suggested that 
as the tumor is growing cells downregulate the expression of chemokines through MAPK-signaling 
pathways in order to evade host antitumor immune responses [265]. Other groups have observed similar 
phenomena in CKR expression. After isolating bone marrow stromal cells and culture them for several 
passages, Honzarenco and his team reported loss of expression from some CKRs, although in this case 
this reaction was followed by a decrease in the proliferation capabilities and higher apoptotic rates 
[340]. 
 
Aside from the molecular mechanisms that reduce chemokine expression capability in tumor cells, we 
observed that these fluctuations of CCL20 expression could influence our in vivo experiments. We saw 
that there was a correlation between the decrease in the CCL20 production capability of B16 cells and 
tumor growth and progression in Wt and CCR6-/- mice. These differences were significantly higher 
between CCR6-/- individuals.  
 
Although our first experiments gave us some hints on how CCL20 and CCR6 could influence melanoma 
progression, the variations in CCL20 expression capability of B16 melanoma cells affected the accuracy of 
our experimental injection model.  
 
Generation of B16-Control and B16-CCL20 cells responded to the need of accurate positive and negative 
controls to study the effect of CCL20 expression by B16 melanoma cells in tumor progression and 
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immunosurveillance. Once generated and tested, inoculation in Wt and CCR6-/- mice gathered all the 
conditions to study the role of CCR6 and CCL20 in vivo, alone and combined. Hence, on one hand we 
could study the effect of CCL20 in melanoma progression in presence/absence of CCR6 and on the other 
hand we used the low/none CCL20 expressing B16-Control cell line to short out the influence of CCR6 
under CCL20 deficiency conditions.  In any case, although B16-CCL20 cells could express high amounts of 
CCL20 under homeostatic conditions, its expression was lost after several passages as well. Therefore in 
pursuit of accuracy, early passage cells had to be used for experimentation.  
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6.2. Characterization of CCR6/CCL20-dependent immune responses in a 
transplantable B16-melanoma model using WT and CCR6-/- mice. 
6.2.1. Impact of CCL20-overexpression by B16 cells on tumor growth kinetics.  
Our mouse model for the study of murine melanoma using B16-CCL20 and B16-Control injected mice 
corroborated our conjectures that CCL20 could influence tumor growth. The outcome of the effect was 
different between Wt and CCR6-/- mice.  
 
On one hand, Wt mice showed slightly smaller tumors at the final stages of the experiment upon CCL20 
overexpression of melanoma cells. The presence or absence of this chemokine did affect neither the 
onset nor the early tumor growth. It was in the last stages of the experiment that tumor growth slowed 
down in B16-CCL20 injected Wt animals.  
 
On the other hand, B16-CCL20 injected CCR6-/- mice showed significantly reduced tumor growth 
compared to their control littermates as well. However, the observed differences in final tumor were 
initiated at early tumor progression stages (days 4-8). Tumor onset in B16-Control injected CCR6-/- mice 
did not differ significantly from Wt experimental groups. In fact, tumor sizes from B16-CCL20 injected Wt 
mice at day 15 were almost similar to the ones from B16-Control CCR6-/- animals at day 15. In these three 
experimental groups tumor growth gradient was significantly higher during the first days after becoming 
visible and got stable over time.  
 
Injecting B16-Control and emulating the conditions of B16-CCL20 tumors by administration of rCCL20 
periodically could reproduce these observations. Moreover, and despite not reaching statistical 
significance, emulating the opposite situation using anti-mCCL20 antibodies in order to hamper CCL20 
effects in B16-CCL20 tumors resulted in a slight increase of tumor growth in CCR6-/-. 
 
On the contrary tumors from B16-CCL20 injected CCR6-/- mice did not become visible till 4-5 days later 
than the rest of the experimental groups and showed a constant tumor growth gradient after that. 
Hence we can differentiate two effects caused by CCL20: An effect on tumor progression in Wt mice and 
on tumor initiation in CCR6-/- mice. Two questions arise from these observations. First, how is it possible 
that CCL20 has such a noticeable impact on animals that lack its unique and exclusive receptor? And 
second, why does CCL20 not cause a similarly significant effect in Wt mice? 
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6.3. The tumor microenvironment 
6.3.1. Cellular components of the tumor microenvironment 
6.3.1.1. TILs in WT mice 
We observed that B16-CCL20 injected Wt mice developed smaller tumors than their control 
littermates. Interestingly the relative amounts of the overall analyzed TILs were similar in both 
experimental groups at the end of the experiment (day 15 after tumor inoculation) with the only 
exception of increased amounts of CCR6+ T-regulatory cells in B16-CCL20 injected mice. More 
differences were observed between groups at day 9 after inoculation where levels of overall pDCs and 
CCR6+ fraction of some immune cell subsets (pDCs, cDCs, CD4+ T-cells and T-regs) were significantly 
higher in B16-Control injected animals.  
 
It could be possible that an accumulation of these immune cell subsets during early stages of 
tumor development could hamper the anti-tumor immune response or simply enhance tumor growth. In 
a recent human study, a correlation between lower amounts of circulating pDCs and negative tumor 
prognosis was observed [341]. It could be possible that pDCs accumulate at the site of the tumor, 
resulting in a pro-tumorigenic outcome. Accumulating amounts of T-regs would also contribute to this 
outcome due to their immunosuppressive function. 
 
On the other hand, the fact that we found increased amounts of CCR6+ immune cells within 
early stage tumors of B16-Control injected mice caught our attention. Regardless of the differences in 
the outcome on melanoma progression, we anticipated higher migration of CCR6+ leucocytes in B16-
CCL20 injected mice (as it is the case for CCR6+ T-regs). It has been reported however, that in some cases 
CCR6 expression by immune cells does not imply a migratory-response to the presence of CCL20 [113].  
 
However, there are also other considerations that could help finding an explanation for our 
observations. The absence or low concentrations of CCL20 at the tumor site leave CCR6 free of any 
ligand, thus making it detectable by FCM antibodies, while CCR6 turnover after CCL20-binding in B16-
CCL20 tumors would be enhanced reducing the time gap when the receptor is free to bind detection 
antibodies. In line with this idea, it is possible that in B16-CCL20 tumors, CCR6+ immune cells migrate to 
regional LNs downregulating CCR6 expression after ligand binding, as reported for some APCs in 
melanoma were downregulation of CCR6 is followed by CCR7 expression, which leads the cells towards 
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regional lymph nodes. A passive diffusion of tumor-produced chemokines towards the LN could be the 
cause of this migration, as has been described in some studies [326]. 
 
Another possible explanation to this phenomenon would be that the differences in CCL20 
concentration within the tumor microenvironment could be modifying the conditions (inducing the 
secretion of other chemokines, for example) that trigger the migration or activation of different immune 
cell subsets. In this situation CCR6+ immune cells could migrate following CCR6-independent chemo-
attractant gradients were CCR6 would play a secondary role. 
6.3.1.2. TILs in CCR6-/- mice 
As it was the case in both experimental groups of Wt mice, the relative amounts of the analyzed 
TILs were similar between the CCR6-/- experimental groups at day 15 after inoculation. This was also the 
case for most of the analyzed immune cell subsets at day 9 with the exception of activated B-cells, B-
regs, overall T-cells and CD4+ T-cells, which were significantly higher in B16-control injected mice at this 
time point. 
 
Considering that the only difference between B16-Control and B16-CCL20 tumors is the release 
of mCCL20 to the tumor microenvironment, differences in TILs could again be explained by changes in 
the cytokine composition of the former. Previous studies have reported similar situations. For instance, 
some years ago Liao and collaborators observed that B-Cells responded to CCL20 without expressing 
CCR6 at protein or mRNA level [114]. This type of observations can be due to indirect effects caused by 
CCL20, or direct effects triggered by different chemokines binding to CCR6, like CCL18 or CCL5 [110].  
 
Regarding the differences we observed in for some TIL subsets, B-cells have been associated with 
good melanoma tumor prognosis due to their role in the activation of T-cells [250]. Surprisingly 
increased amounts of these cells, alongside with T-cells, resulted in increased tumor progression, unlike 
in B16-CCL20 injected CCR6-/- mice. In recent years, infiltrating B-cells are increasingly being reported in 
melanoma and other tumor types, and their contribution to the final outcome has led to antagonistic 
conclusions [342]. It is being debated that the possible origins of this controversy could originate from 
differences in the specific micro-anatomical locations infiltrated by B-cells, the different surface markers 
used and the assumption that B-cells migrate as a result of a tumor antigen-specific immune response or 
simply as a response to inflammatory signals [343].  
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In our study, we found increased levels of B-regs within the B-cell fraction. High amounts of this subset 
could be the cause of increased tumor growth due inhibition of the immune responses, in the same way 
that it has been reported in various cancers [344]. 
 
As described in section 5.7, no differences were found in the studied immune cell ratios within Wt or 
CCR6-/- experimental groups. CD8+/CD4+, CD8+/Foxp3+ and CD8+/pDCs ratios were higher in Wt than in 
CCR6-/- groups at day 15. However, despite of these differences B16-CCL20 injected Wt and B16-Control 
injected CCR6-/- groups displayed similar tumor sizes at the end of the experiment. On the other hand, 
despite of the similarities in the analyzed immune cell ratios, tumor onset, growth and progression were 
significantly different between the two CCR6-/- experimental groups.  
 
While we cannot conclude that CD8+ ratios with respect to CD4+ T-cells, T-regs and pDCs are irrelevant 
based on these observations, additional research is required to clarify the impact of these immune cell 
ratios on melanoma progression. It should be mentioned as well that detecting cells within the tumor 
gives valuable information but state of the activation of those cells may need to be analyzed in order to 
more accurately elucidate the magnitude and type of the immune response in each case.   
 
6.3.2. Soluble components of the tumor microenvironment 
Besides changes in the composition of TILs, differences in tumor growth caused by CCL20 could also be 
explained by changes in the tumor microenvironment. As commented previously during the 
introduction, it is well known that CCL20 can interact with various elements of the tumor 
microenvironment. For instance, Hasan and collaborators showed in 2006 that cathepsins present within 
melanoma are able to bind, cleave and inactivate CCL20 [297]. In the same line, it is highly likely that 
CCL20 could bind one or more proteins or elements within the tumor microenvironment and 
activate/block certain signaling pathways.  
 
In our experimental model, CCL20 concentration in the microenvironment of B16-CCL20 injected CCR6-/- 
mice would create an imbalance of certain components that would end up affecting tumor growth like, 
for example, the expression or downregulation of specific growth factors necessary for tumor 
progression, or by altering the adhesion to collagen [345]. On the contrary, in Wt mice surrounding CCR6 
expressing cells/tissues would take CCL20, thus reducing its concentration at the tumor 
microenvironment. The only difference we could detect between the TMEs of our experimental groups 
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was a reduction on the concentration of INF-ɣ in B16-CCL20 injected CCR6-/- mice. Nevertheless further 
research is necessary in order to test this hypothesis. 
 
Finally, changes in the composition of the tumor microenvironment could be the indirect cause of 
differences in TIL composition between B16-CCL20 and B16-Control injected mice. It is highly likely that 
in addition to the detected changes in INF-ɣ other cytokines could be affected, thus attracting or 
activating different subsets of immune cells. 
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6.4. TDLN Immune cell compositions  
Besides analyzing TIL in our four experimental groups, we were also interested in the immune cell 
composition of the TDLN. It has been observed that tumor produced cytokines and chemokines can 
diffuse from the skin to the regional lymph nodes [346] and as already commented, TILs like some APCs 
migrate towards regional lymph nodes once they have reside within the tumor in order to enhance the 
antitumor immune response [326]. In a recent study, researchers were able to enhance the anti-tumor 
immune response in mice by injecting with a DNA vaccine consisting on the CCL20 sequence tagged with 
the melanoma antigen Gp100. In treated mice, enhanced APC activation of CD4+ and CD8+ resulted in a 
better prognostic outcome [299]. In sum, relation between CCL20/CCR6 axis and LN related immune 
responses had to be analyzed in our project as well. 
 
6.4.1. TDLN immune composition in Wt mice 
 At day 4 after tumor inoculation, the TDLN immune cell composition of B16-Control and B16-
CCL20 injected mice was vastly similar. The only observed differences were found in B16-Control Wt 
animals, which showed significantly higher numbers of pDCs. Interestingly amount of TIL pDCs in this 
experimental group was significantly higher at day 9 as well. 
 
Similar findings were observed at day 9 after tumor inoculation, where the only observed 
differences were in terms of B1/K cells, which were significantly higher in the B16-CCL20 injected group. 
Later on at day 15, a higher accumulation of CCR6+ CD4+ T-cells and CCR6+ T-regs was observed in this 
group as well. The accumulation of CCR6+ immune cells in regional lymph nodes of B16-CCL20 injected 
mice could point out that B16 derived CCL20 could have been diffused from the skin towards the LN as it 
has been previously reported for skin-derived CCL27 [326]. 
 
6.4.2. TDLN immune composition in CCR6-/- mice 
Interestingly, despite highly significant differences in final tumor size, the onset and progression, 
immune cell composition of TDLN of B16-Control and B16-CCL20 injected CCR6-/- mice was highly similar 
for all immune cell subsets selected at all time points analyzed. The only exception was observed at day 4 
after tumor inoculation, where B16-CCL20 injected animals showed higher levels of pDCs compared to 
controls.  
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This phenomenon was also observed at day 4 in TDLN from B16-Control injected Wt mice. This 
could point out to a critical role of pDCs at early tumor stages. As we have observed before, B16-Control 
injected CCR6-/- mice had higher relative amounts of certain T-cell and B-cell subsets at day 9 after tumor 
inoculation. It can be hypothesized that early accumulation of pDCs in TDNL of B16-CCL20 injected CCR6-
/- mice would hamper the migration of these subsets towards the tumor, leading to a slowdown of tumor 
growth.  
 
Additional research is required in order to analyze the precise role of those T-cell and B-cell 
subsets in the overall tumor outcome at early stages. Nevertheless, the fact that increased CCL20 
expression at the tumor site promotes early accumulation of pDCs in the TDLN of CCR6-/- opens up new 
questions that would require further research as well.  
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6.5. Study of potential autocrine effects of CCR6/CCL20 interactions in melanoma 
Besides functioning as a chemoattractant of immune cells through CCR6, CCL20 can play different roles 
within tumors interacting/affecting other components or processes, or even the same tumor cells.  
 
6.5.1. Can CCL20 stimulate B16 tumor cells in an autocrine manner? 
Co-expression of CCR6 and CCL20 by malignant tumor cells has been reported in various epithelial 
cancers (nasopharyngeal tumors, colorectal cancer, lung and pancreatic adenocarcinomas), pointing to 
autocrine self-stimulation pathways [176]. Regarding melanoma, in a recent publication Samaniego and 
collaborators suggested that CCL20 interacts with cells in the tumor stroma through a paracrine signaling 
loop. While this may provide a plausible mechanism that could explain our observations in Wt mice, it 
cannot be applied to the CCR6-/- model [141].  
 
As commented previously, the B16 melanoma cell lines used in this project were CCR6+/+. Thus, this 
opens the possibility for a hypothetical autocrine signaling pathway in which B16-derived CCL20 would 
bind CCR6 receptors on the surface of the same tumor cells triggering a signal affecting the tumorigenic 
capability of melanoma cells. In line with this hypothesis, other chemokine axes have been found to 
affect melanoma progression in an autocrine manner. This is the case of CXCL1, CXCL2 and CXCL8, that 
regulate melanoma tumor progression influencing tumor growth, angiogenesis and metastasis through 
CXCR1 and CXCR2 [347]; or CXCR4 and CXCL12, which can regulate local invasion and metastasis [277]. In 
the case of CCL20, Several reports have pointed out autocrine interactions of this chemokine with cancer 
cells such in bone metastasis [348], lung adenocarcinoma [349], colorectal liver metastases [350] or 
human erythroid leukemia [351] for example. Additionally, CCL20 appears to have a direct role over the 
regulation of CSCs [352]. 
 
To test this hypothesis in our model, we first studied CCR6 expression in our melanoma cell lines. We 
were able to detect CCR6 expression by B16-CCL20 cells, but not by B16-parental or B16-Control cell 
lines. However CCL20 did not affect in vitro growth in neither of the cell lines and, although upon high 
concentrations of CCL20 in the medium the expression of certain pro-inflammatory cytokines was 
reduced, the effect was the same in both cell lines.  
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Pointing to a possible CCL20 autocrine-loop in B16-CCL20 tumors, B16-CCL20 showed higher migration 
rates than B16-Control cells in a wound healing assay in vitro , and stimulation with CCL20 increased the  
wound healing rate even more in B16-CCL20 cells but had no effect at all in B16-Control cells.  
 
6.5.2. Does CCL20 upregulate CCR6 expression? 
When B16-Control injected CCR6-/- mice are inoculated periodically with recombinant CCL20, we observe 
significant differences in tumor growth compared to controls. It seems possible that upon high 
concentrations of CCL20 in the tumor microenvironment, B16 cells would upregulate CCR6 expression. 
CCR6 upregulation upon CCL20 stimulation has been reported in hepatocellular carcinoma [353]. In our 
case, the only evidence we have so far of a direct effect of CCL20 on B16-Control cells is that in presence 
of the former, the expression of some cytokines are downregulated in the latter. This effect could also be 
observed in B16-CCL20 cells and the parental B16 cell line.  
 
However, if CCL20 would affect tumorigenic capabilities of B16 cells through an autocrine loop, why do 
we not observe delayed onset and reduced tumor growth in Wt animals as well? Theoretically, in Wt 
mice the low amounts of CCL20 produced by early stage tumors could be taken up by CCR6-expressing 
cells from surrounding tissues, such as fibroblasts or keratinocytes in contrast to the CCR6-deficient 
microenvironment CCR6-/- mice.  This hypothetical situation in which B16 produced CCL20 would be 
arrested and taken up by surrounding tissue would emulate conditions in B16-Control injected Wt and 
CCR6-/- animals where CCL20 presence is weak or non-existent (Scheme 6) 
 
In order for this hypothesis to be tested, further research is needed, in particular on the precise effect of 
a hypothetical autocrine-signaling pathway. Generation of a CCR6-/- CCL20-expressing B16 melanoma cell 
line, alongside with tumor injection models using immune-deficient mice could contribute to elucidate 
this hypothesis. 
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CCL20 autocrine signaling in B16-CCL20 melanoma cells in CCR6-/- mice 
 
CCL20 capture by CCR6-expressing tumor microenvironment in Wt mice 
 
Scheme 6. Theoretical Model for B16 derived mCCL20 targets in B16-CCL20 injected Wt and CCR6-/- 
mice. (Top) In CCR6-/-, B16-derived CCL20 accumulates at the tumor site, opening the possibility for a 
self-stimulatory, autocrine pathway. (Bottom) In Wt mice, B16-derived CCL20 is being captured by a 
CCR6-expressing microenvironment, thus reducing its concentration and self-stimulatory properties at 
tumor site. 
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6.6. Conclusions and future insights 
 
We have demonstrated that B16-derivede CCL20 is able to reduce tumor progression in Wt mice and 
plays a key role on tumor onset, growth and progression in CCR6-/- mice, pointing to a decisive role of 
this chemokine for melanoma pathogenesis. Additionally, with this project we have contributed to more 
comprehensively depict the influence of CCR6 and CCL20, alone and combined, on the cellular and 
soluble immune milieu within melanoma tumors and the regional skin-draining lymph nodes. While our 
contribution will help to clarify some aspects of complexity that still surround the CCR6/CCL20 axis in 
malignant diseases the role of this chemokine axis in melanoma is still far from being completely 
understood and we have to acknowledge the limitations of our study. The absence of a commercially 
available antagonist for CCR6 together with the lack of a reliable CCL20-/- mouse model hampers the 
study of the CCR6/CCL20 axis. Further research is required, in particular in order to elucidate the precise 
role and function of described CCR6+ immune cell subsets, the identification of the effects and targets of 
CCL20 expressed in the melanoma microenvironment and a possible impact on CSCs, tumor angiogenesis 
and metastasis. 
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